<?xml version="1.0" ?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text xml:lang="en">
			<front>Current Neuropharmacology <lb/>ISSN: 1570-159X <lb/>eISSN: 1875-6190 <lb/>SCIENCE <lb/>BENTHAM <lb/>Impact <lb/>Factor: <lb/>4.8 <lb/>Send Orders for Reprints to reprints@benthamscience.net <lb/>974 <lb/>Current Neuropharmacology, 2025, 23, 974-995 <lb/>RESEARCH ARTICLE <lb/>In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) <lb/>Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: <lb/>Implications for Suicidal Ideation and Substance Use Disorder <lb/>Alireza Sharafshah 1 , Kai-Uwe Lewandrowski 2,3 , Mark S. Gold 4 , Brian Fuehrlein 5 , John Wesson <lb/>Ashford 6 , Panayotis K. Thanos 7,17 , Gene Jack Wang 8 , Colin Hanna 7 , Jean Lud Cadet 9 , Eliot L. <lb/>Gardner 10 , Jag H. Khalsa 11,12 , Eric R. Braverman 13 , David Baron 14 , Igor Elman 15,17,* , Catherine A. <lb/>Dennen 16 , Abdalla Bowirrat 17 , Albert Pinhasov 17 , Edward J. Modestino 18 , Paul R. Carney 19 , Rene <lb/>Cortese 20 , Rossano Kepler Alvim Fiorelli 21 , Sergio Schmidt 22 , Aryeh R. Pollack 13 , Rajendra D. <lb/>Badgaiyan 13,23 and Kenneth Blum 3,13,14,17, 20,24,25,* <lb/>1 Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; <lb/>2 Department of Orthopaedics, Fundación Universitaria Sanitas Bogotá D.C. Colombia; 3 Division Personalized Pain <lb/>Research and Education, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ., 85712, USA; 4 Department <lb/>of Psychiatry, Washington University School of Medicine, St. Louis, MO., 63110, USA; 5 Department of Psychiatry, Yale <lb/>University School of Medicine, New Haven CT., 06511, USA; 6 Department of Psychiatry &amp; Behavioral Sciences, Stan-<lb/>ford University, Palo Alto, CA Director, War Related Illness &amp; Injury Study Center, VA Palo Alto Health Care System, <lb/>Palo Alto, CA, 94305, USA; 7 Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical <lb/>Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosci-<lb/>ences, State University of New York at Buffalo, Buffalo, NY., 14260, USA; 8 Laboratory of Neuroimaging, National Insti-<lb/>tute of Alcohol Abuse &amp; Alcoholism, Bethesda, MD, 20892, United States; 9 Molecular Neuropsychiatry Research <lb/>Branch, NIH National Institute on Drug Abuse, Bethesda, MD., 20892, USA; 10 Neuropsychopharmacology Section, In-<lb/>tramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD., 20892, <lb/>USA; 11 Division of Therapeutics and Medical Consequences, Medical Consequences of Drug Abuse and Infections <lb/>Branch, National Institute on Drug Abuse, NIH, Special Volunteer, Industrial Drive, Gaithersburg, MD., 20892, The <lb/>USA; 12 Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University School of <lb/>Medicine, Washington, NWDC., 20037, The USA; 13 The Kenneth Blum Behavioral &amp; Neurogenetic Institute, LLC., Aus-<lb/>tin, TX., 78701, USA; 14 Center for Sports, Exercise, Mental Health, Western University Health Sciences, Lebanon, OR., <lb/>91766, USA; 15 Cambridge Health Alliance, Harvard Medical School, Cambridge, MA., 02115, USA; 16 Department of <lb/>Family Medicine, Jefferson Health Northeast, Philadelphia, PA., USA; 17 Department of Molecular Biology, Adelson <lb/>School of Medicine, Ariel University, Ariel, Israel; 18 Brain &amp; Behavior Laboratory, Department of Psychology, Curry <lb/>College, Milton, MA., 02186, USA; 19 Departments of Pediatrics and Neurology, University of Missouri School of Medi-<lb/>cine, Columbia, 65212, Missouri, USA; 20 Departments of Pediatrics and Obstetrics, Gynecology and Women&apos;s Health. <lb/>School of Medicine. University of Missouri, Columbia, MO, 65212, USA; 21 Department of General and Specialized Sur-<lb/>gery, Gaffrée e Guinle University Hospital, Federal University of the State of Rio de Janeiro (UNIRIO), Rio de Janeiro, <lb/>Brazil; 22 Post-Graduate Program in Neurology, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Bra-<lb/>zil; 23 Department of Psychiatry, Texas Tech University Health Sciences, School of Medicine, Midland, TX., 79430, USA; <lb/>24 Department of Psychiatry, Wright State University Boonshoft School of Medicine and Dayton VA Medical Center, <lb/>Dayton, OH., 45435, USA; 25 Department of Psychiatry, Human Integrated Services Unit, University of Vermont Center <lb/>for Clinical &amp; Translational Science, College of Medicine, Burlington, VT, 05401, USA <lb/>Abstract: Introduction: Glucagon-Like Peptide-1 Receptor (GLP1R) agonists have become wide-<lb/>spread anti-obesity/diabetes pharmaceuticals in the United States. <lb/>Aim: This article aimed to provide our current knowledge on the plausible mechanisms linked to the <lb/>role of Ozempic (Semaglutide), which is generalized as one of the anti-addiction compounds. <lb/>Methods: The effects of GLP1R agonists in Alcohol Use Disorder (AUD) and substance use disorder <lb/>(SUD) are mediated, in part, through the downregulation of dopamine signaling. We posit that while <lb/>GLP1R agonism could offer therapeutic advantages in hyperdopaminergia, it may be detrimental in <lb/>patients with hypodopaminergia, potentially leading to long-term induction of Suicidal Ideation (SI). <lb/>The alleged posit of GLP1 agonists to induce dopamine homeostasis is incorrect. This study refined <lb/>31 genes based on the targets of Ozempic, GLP1R, and related enzymes for SI and 10 genes of the <lb/>A R T I C L E H I S T O R Y <lb/>Received: July 19, 2024 <lb/>Revised: October 18, 2024 <lb/>Accepted: October 28, 2024 <lb/>DOI: <lb/>10.2174/011570159X349579241231080602 <lb/>1875-6190/25 <lb/>2025 Bentham Science Publishers <lb/>© 2025 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode <lb/>PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 975 <lb/>Genetic Addiction Risk Score (GARS) test. STRING-MODEL refined 29 genes, and further primary <lb/>analyses indicated associations of GLP1R with DRD3, BDNF, CREB1, CRH, IL6, and DPP4. <lb/>Results: In-depth silico enrichment analysis revealed an association between candidate genes and <lb/>depressive phenotypes linked with dopaminergic signaling. Finally, through primary and in-depth <lb/>silico analyses, we demonstrated multiple findings supporting that GLP1R agonists can induce de-<lb/>pression phenotypes. <lb/>Conclusion: Our findings suggest that associated polymorphisms seem to have overlapping effects <lb/>with addictive behaviors of Reward Deficiency Syndrome (RDS) and dopamine regulation. Conse-<lb/>quently, GLP1R agonists may represent a double-edged sword, potentially triggering both anti-<lb/>addictive effects and SI by exacerbating depressive phenotypes. Thus, we encourage the scientific <lb/>community to perform further empirical clinical studies to confirm this proposed pathway. <lb/>Keywords: GLP1, Ozempic, suicide ideation, substance use disorder, dopamine homeostasis, in-depth in silico. <lb/></front>

			<body>1. INTRODUCTION <lb/>Glucagon-like peptide-1 Receptor (GLP1R) agonists <lb/>have become extensive anti-obesity/diabetes medications in <lb/>the United States. This study aimed to investigate the poten-<lb/>tial mechanisms associated with Ozempic (Semaglutide), <lb/>which is generalized as one of the anti-addiction compounds. <lb/>The impacts of GLP1R agonists on substance use disorder <lb/>(SUD) and alcohol use disorder (AUD) are partially mediat-<lb/>ed by dopamine signaling downregulation. We hypothesize <lb/>that, whereas GLP1R agonism may be beneficial for treating <lb/>hyperdopaminergia, it may be detrimental for treating hypo-<lb/>dopaminergia, perhaps resulting in the long-term induction <lb/>of suicidal ideation (SI). Thus, by examining prior reports and <lb/>our analyses, we will investigate the aforementioned idea. <lb/>Globally, it is estimated that while 1 in 8 people globally <lb/>are considered obese, close to 300 million individuals suffer <lb/>from AUD, including approximately 150 million individuals <lb/>with alcohol dependence [1, 2]. Most compelling is that the <lb/>World Health Organization (WHO) estimated that the harm-<lb/>ful qualities of alcohol use and abuse account for approxi-<lb/>mately 5% of premature fatalities. As such, the WHO notes <lb/>that alcohol use and abuse is a leading cause of preventable <lb/>fatalities worldwide. It is considered to be linked to consum-<lb/>ers of alcohol having a lower rate of treatment than other <lb/>psychiatric disorders [3]. It is also true that AUD is linked to <lb/>a high premature mortality rate, which has been associated <lb/>with dopamine dysregulation, including the DRD2 A1 allele, <lb/>which is over-represented in alcohol-dependent individuals <lb/>[4]. In one study, this allele has also been associated with a <lb/>highly increased mortality rate in alcohol-dependent individ-<lb/>uals [4]. Along similar lines, it has been estimated by the <lb/>United Nations 2023 World Drug Report that globally, over <lb/>354 million humans will use illicit drugs in 2021 [5]. Out of <lb/>the 354 million, 218 million were attributed to cannabis, 60 <lb/>million to opioids, 21 million to cocaine, 20 million to ecsta-<lb/>sy, and 35 million to amphetamine [5]. These statistics are <lb/>morphed by the unfortunate fact that the prevalence of to-<lb/>bacco use is over 1 billion. Tobacco use is one of the highest <lb/>preventable causes of premature death, while eight million <lb/>humans die due to tobacco-related diseases annually [6-8]. <lb/>While there are FDA pharmaceuticals approved for alcohol. <lb/></body>

			<front>*Address correspondence to these authors at the Division Personalized Pain <lb/>Research and Education, Center for Advanced Spine Care of Southern Ari-<lb/>zona, Tucson, AZ., USA; E-mail: drd2gene@gmail.com (K.B.); Cambridge <lb/>Health Alliance, Harvard Medical School, Cambridge, MA., USA; <lb/>E-mail: dr.igorelman@gmail.com (I.E.) <lb/></front>

			<body>Opioid, and tobacco misuse, albeit these treatments are not <lb/>without adverse effects and even addiction liability (e.g., <lb/>methadone). There is currently no treatment for cannabis or <lb/>psychostimulant disorders. The search for safe and effective <lb/>modalities to treat all Reward Deficiency Syndrome (RDS) <lb/>behaviors continues to be actively explored. Research has <lb/>shown that people suffering from substance and non-<lb/>substance behavioral addictions (i.e., obesity/food addiction) <lb/>have overlapping brain dysregulation and share genetic and <lb/>epigenetic mechanisms, particularly hypodopaminergia [9, <lb/>10]. Therefore, hypodopaminergia could exist in an astonish-<lb/>ing number of people not only in the USA but also globally. <lb/>While Howes &amp; Kapur [10] correctly point out that dopa-<lb/>mine is currently the only known finite reward molecule, its <lb/>regulation, and neuronal release are a function of many risk <lb/>factors beyond DNA antecedents that are linked to reward <lb/>deficiency [9]. These include but are not limited to stress, <lb/>trauma, obstetric complications, drug use, genetic and epige-<lb/>netic insults that reduce presynaptic striatal dopaminergic <lb/>function. Our proposal is to balance brain neurotransmitters <lb/>by using positive modulation targeted at both upstream and <lb/>downstream pathways in order to overcome substance and <lb/>non-substance behavioral addictions. Thus providing normal <lb/>or close to normal dopamine release at the various brain re-<lb/>gions, especially the Ventral Tegmental Area (VTA) and <lb/>Nucleus Accumbens (NAc). In terms of the Brain Reward <lb/>Cascade (BRC) that was first published in 1989, it is note-<lb/>worthy to add glucagon-like peptide 1 (GLP-1) receptors to <lb/>the model. One advantage of the GLP-1 receptor agonists in <lb/>relation to obesity is that they play a significant role in in-<lb/>ducing insulin secretion after meals and aid in weight loss by <lb/>encouraging satiety and delaying stomach emptying [11-13]. <lb/>In addition, research has shown that GLP-1 receptor agonists <lb/>are very effective at reducing A1c and cardiovascular disease <lb/>in patients with existing Atherosclerotic Cardiovascular Dis-<lb/>ease (ASCVD) [14-21]. Research has also shown that GLP-1 <lb/>receptor agonists have an overall decrease in mortality in <lb/>individuals with cardiovascular disease and type 2 diabetes <lb/>[22, 23]. Furthermore, many have begun to take a keen inter-<lb/>est in the role of GLP-1 receptors and dopaminergic regula-<lb/>tion in the mesolimbic system of the human brain [24, 25] <lb/>and the potential role of GLP-1 in the attenuation of, for ex-<lb/>ample, alcohol intake from both human genetic association <lb/>studies and mouse models of alcohol dependence. However, <lb/>while there are some reports about the various agonists <lb/>of GLP-1 with some positive effects in curtailing food intake <lb/>[12] and even AUD [26, 27], the agonistic effects of GLP-1 <lb/></body>

			<page>976 </page>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/>Sharafshah et al. <lb/></note>

			<body>Fig. (1). The mesolimbic brain reward cascade. This figure illustrates the interaction of some well-known brain reward cascade (BRC) neuro-<lb/>transmitter pathways. Environmental stimulation initiates the release of serotonin (5-HT) in the hypothalamus, which in turn, for example, via <lb/>5 HT-2 A receptors activates (green equal sign) the subsequent release of opioid peptides from opioid peptide neurons. Then, in the Substan-<lb/>tia Nigra (SN), the opioid peptides bind to two distinct opioid receptors with different mechanism of action. One is through the mu-opioid <lb/>receptor that inhibits (red hash sign) GABA-ergic neurons (possibly via an opioid peptide like enkephalins). The second stimulates canna-<lb/>binoid neurons (for example, the Anandamide and 2-arachidonoylglycerol) (green equal sign) through beta-endorphin-linked delta receptors, <lb/>which inhibit GABAA neurons. When activated, cannabinoids, primarily the 2-arachidonoylglycerol neurons, can disinhibit (green hash sign) <lb/>GABA-ergic neurons indirectly by CB1 receptor activation. Glutamatergic neurons in the Dorsal Raphe Nuclei (DRN) disinhibit GABA neu-<lb/>rons in the SN indirectly through GLU M3 receptor activation (green hash sign). When disinhibited, GABAA neurons will powerfully inhibit <lb/>(red hash signs) VTA glutaminergic drive via GABAB 3 receptors. At the Nucleus Accumbens (NAc), Acetylcholine (ACH) neurons may <lb/>inhibit (red hash sign) muscarinic and stimulate Nicotinic (green hash) receptors. Glutamate neurons in the VTA will project to dopamine <lb/>neurons through NMDA receptors (green equal sign) to release dopamine at the NAc. (with permission from Blum et al.). (A higher resolu-<lb/>tion/colour version of this figure is available in the electronic copy of the article). <lb/>are very complex (Fig. 1). Interestingly, Glucagon-like pep-<lb/>tide 1 (GLP-1) regulates food intake, insulin production, and <lb/>metabolism. Fortunately, a recent study demonstrated that <lb/>pancreatic α-cells-secreted (intraislet) GLP-1 effectively <lb/>promotes maternal insulin secretion and metabolic adapta-<lb/>tion during pregnancy. Specifically, Qiao et al. [28, 29] <lb/>showed a progressive reduction in maternal blood GLP-1 <lb/>concentration. GLP-1 receptor agonist injection in late preg-<lb/>nancy significantly reduced fetal body weight, even after <lb/>restoration of maternal blood glucose concentration. GLP-1 <lb/>receptor activation significantly reduced the placental laby-<lb/>rinth area, expression of some nutrient transporters, and ca-<lb/>pillary development. Qiao et al. suggested that reducing ma-<lb/>ternal blood GLP-1 levels is a physiological adaptation pro-<lb/>cess that benefits placental development and fetal growth [28]. <lb/>Impairment of glucoregulatory function, which is conse-<lb/>quential to the addiction neuropathology, can worsen Sub-<lb/>stance Use Disorder (SUD) and polydrug abuse. Therefore, it <lb/>is reasonable to expect amelioration of addictive behaviors/ <lb/>symptoms through the improvement of metabolic function <lb/>(i.e., using GLP-1 receptor agonists). Research has demon-<lb/>strated that the effects of GLP-1 in alcohol use disorder and <lb/>SUD are mediated partly through the downregulation of do-<lb/>pamine signaling and even enhanced catabolism in both the <lb/>synapse and mitochondria due to GLP1 agonistic increase in <lb/>the gene expression such as Catechol-O-methyltransferase <lb/>(COMT) and Monoamine Oxidase A (MAOA) [30, 31]. <lb/>While this may have some important relevance in the short <lb/>term, where hyperdopaminergia exists, it is important to cau-<lb/>tion against promoting chronic stimulation via a GLP-1 ago-<lb/>nist. Recent findings have shown a link between GLP-1 re-<lb/>ceptor agonists and several genes within the dopaminergic <lb/>pathway. Therefore, stimulation of GLP-1 receptor agonists, <lb/>especially chronically, can lead to the dysregulation of the <lb/>dopaminergic pathway, which in turn can cause depression, <lb/>suicidality, and other mood disturbances [9, 16, 32-40]. <lb/>In sum, while employing GLP-1 agonism may offer ther-<lb/>apeutic benefits in instances of recognized hyperdopaminer-<lb/>gia, it could be determinantal in patients with hypodopamin-<lb/>ergia. Most recently, Klausen et al. [9, 41] suggested that <lb/>the therapeutic effects of GLP1R agonists on AUD and SUD <lb/>seem to be mediated partly through the downregulation of <lb/>dopaminergic signaling [41]. While this may have some im-<lb/>portant relevance in the short term, we would like to point <lb/>out a cautionary pitfall in promoting chronic stimulation via <lb/>a GLP1R agonist, like Exenatide, as an anti-craving agent. <lb/>It behooves the scientific community to understand the <lb/>complexity of GLP1R&apos;s physiology and molecular neurobio-<lb/>logical actions. Importantly, the scientific and clinical com-<lb/>munity are actively exploring both the neurogenetic and epi-<lb/>genetic mechanisms related to, for example, &apos;pre-addiction&quot; <lb/>polymorphic profiles. Understanding the potential of people <lb/>born with DNA-linked GARS genes and, hence, hypodopa-<lb/>minergia is crucial. Having this DNA data may provide im-<lb/></body>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>977 <lb/></page>

			<body>portant genetic information related to both those who require <lb/>and benefit from GLP1R agonistic therapy. It is our hypothe-<lb/>sis that in patients with genotypes displaying low dopamine <lb/>function via reward gene polymorphisms assessed with <lb/>GARS, the long-term administration of GLP1 agonists <lb/>should be cautioned. This notion is based on reported exper-<lb/>iments indicating GLP1 agonists induce dopamine dysregu-<lb/>lation (PUBMED 69 articles listed using word term GLP1 <lb/>agonists and dopamine) [42] that requires possibly modified <lb/>dosage to prevent any further downregulation of dopamine <lb/>release at the nucleus accumbens (Fig. 1). <lb/>Accordingly, Klausen et al. [34] showed that exenatide <lb/>significantly attenuated fMRI alcohol cue reactivity in the <lb/>ventral striatum and septal area, which are critical brain re-<lb/>gions for drug reward and addiction, even though it did not <lb/>significantly reduce the number of heavy drinking days when <lb/>compared with placebo in AUD patients who underwent <lb/>functional MRI (fMRI) and single-photon emission CT <lb/>(SPECT) brain scans. This work further suggested the induc-<lb/>tion of a blunted reward system following the action of <lb/>GLP1agonists. Numerous studies have unfortunately shown <lb/>that blunted brain reward circuitry in the mesolimbic system <lb/>increases a person&apos;s susceptibility to addiction [35-41]. <lb/>Along these lines, it is indeed noteworthy that in at least <lb/>1,580 articles listed in PUBMED using the term &quot;Reward <lb/>Deficiency&quot; (by the date: 28 June 2024), the primary culprit is <lb/>a reduced dopaminergic function (hyperdopaminergic), that <lb/>leads to aberrant craving behavior for both substance and non-<lb/>substance behavioral addictions. Studies have shown that the <lb/>exenatide (exendin-4) that passes the blood-brain barrier binds <lb/>to GLP1R expressed on the inhibitory GABAergic medium <lb/>spiny neurons in the NAc shell [11, 43-62]. <lb/>It is known that GLP-1 analogs act to attenuate food in-<lb/>take and body weight, including various hypothalamic nuclei <lb/>(arcuate nucleus of the hypothalamus, periventricular hypo-<lb/>thalamus, lateral hypothalamic area), hindbrain nuclei (para-<lb/>brachial nucleus, medial nucleus tractus solitarius), hippo-<lb/>campus (ventral subregion; vHP), and nuclei embedded <lb/>within the mesolimbic reward circuitry (VTA and NAc) [63]. <lb/>Accordingly, Volkow et al. pointed out that disinhibition/ <lb/>stimulation of dopaminergic VTA neurons plays a role in the <lb/>reinforcing effects of alcohol, nicotine, and opioid [12]. In <lb/>fact, it has been observed that GLP1Rs are localized on mouse <lb/>cortical and hippocampal synaptic boutons, specifically on <lb/>glutamatergic and GABAergic nerve terminals. Activation by <lb/>exendin-4 increased the release of either [ 3 H]d-aspartate or <lb/>[ 3 H]GABA [14]. It is well-known that in the mesolimbic sys-<lb/>tem, enhancing GABAergic function and neuro-activation <lb/>significantly reduces NAc dopamine release [15]. <lb/>Specifically, it was reported that both diazepam and mus-<lb/>cimol attenuate dopamine release and that decreases in do-<lb/>pamine release following GABA A receptor activation is in-<lb/>hibited by co-application of a GABA B receptor antagonist. <lb/>These findings support the notion that activation of GABA A <lb/>receptors in the NAc reduces dopamine release by disinhibi-<lb/>tion of local GABA signaling and subsequent activation of <lb/>GABA B receptors [64]. <lb/>Research has shown that GLP1R agonists can affect <lb/>binge-like alcohol drinking. Chuong et al. reported that <lb/>semaglutide dose-dependently reduced binge-like alcohol <lb/>drinking in mice [16]. A similar effect was also observed on <lb/>the intake of other caloric/noncaloric solutions. Semaglutide <lb/>also reduced binge-like and dependence-induced alcohol <lb/>drinking in rats. Additionally, semaglutide increased sIPSC <lb/>frequency in CeA and ILC neurons from alcohol-naive rats, <lb/>suggesting enhanced GABA release. The authors concluded <lb/>that the GLP1R analogue semaglutide decreased alcohol <lb/>intake across different drinking models and species and <lb/>modulated central GABA neurotransmission, which would <lb/>reduce dopaminergic signaling and could then lead to &quot;psy-<lb/>chological extinction&quot; [16]. <lb/>Finally, as of July 2023, the European Medicines Agency <lb/>(EMA) has begun a genetic analysis through reviewing data <lb/>regarding the risk of suicidal thoughts and thoughts of self-<lb/>harm associated with GLP1R agonists, including Ozempic <lb/>(semaglutide), Saxenda (liraglutide), and Wegovy (semag-<lb/>lutide) [65]. The Icelandic Medicines Agency prompted this <lb/>genetic analysis in response to reports of suicidal thoughts <lb/>and self-harm among patients taking liraglutide and semag-<lb/>lutide medications. Authorities are currently reviewing ap-<lb/>proximately 150 reports of potential suicide attempts and <lb/>self-harm incidents. Furthermore, from 2010-2023 the FDA <lb/>has received 265 reports of suicidal thoughts in patients tak-<lb/>ing GLP1R agonists, particularly tirzepatide, liraglutide, and <lb/>semaglutide, prompting a review of these medications [66]. <lb/>Additionally, a recent retrospective pharmacovigilance study <lb/>of the European Pharmacovigilance database was conducted <lb/>for the period from 1 January 2018 to 10 July 2023 [67]. <lb/>Disproportionality analyses (reporting odds ratio, ROR) were <lb/>performed to assess the reporting probability of suicidal <lb/>events among GLP-1 RAs. A total of 230 reports of suicidal <lb/>events were identified. The most reported GLP-1 RA was <lb/>liraglutide (38.3%), followed by semaglutide (36.5%) and <lb/>dulaglutide (16.1%). The most reported events were suicidal <lb/>ideation (65.3%) and suicide attempt (19.5%). Dispropor-<lb/>tionality analysis found a higher reporting probability of <lb/>suicidal events for semaglutide than dulaglutide (ROR, 2.05; <lb/>95% CI, 1.40-3.01) and exenatide (ROR, 1.81; 95% CI, <lb/>1.08-3.05). Suicidal events were mostly reported with <lb/>semaglutide and liraglutide, which were also associated with <lb/>significantly higher reporting probabilities compared to other <lb/>GLP1 RAs. In another study [68], during the study period, <lb/>31,444 adverse event reports were identified: semaglutide <lb/>(n = 13,956; 44.4%), liraglutide (n = 16,748; 53.2%), and <lb/>tirzepatide (n = 740; 2.3%). There were 372 reports with <lb/>psychiatric adverse event reports (n = 372; 1.18%) with <lb/>a total of 481 adverse events. Women accounted for 65% <lb/>(n = 242) of these reports. Depression was the most commonly <lb/>reported adverse event (n = 187; 50.3%), followed by anxie-<lb/>ty (n = 144; 38.7%) and suicidal ideation (n = 73; 19.6%). <lb/>Nine deaths (8 with liraglutide and 1 with semaglutide) and <lb/>11 life-threatening outcomes (4 associated with liraglutide <lb/>and 7 with semaglutide) were reported. The fatal outcomes <lb/>occurred primarily among men (8 out of 9), resulting from <lb/>completed suicidal attempts and depression. Furthermore, <lb/>various pharmacovigilance analyses and notifications from <lb/>different regulatory agencies have documented the occur-<lb/>rence of suicidal thoughts and self-injurious behavior associ-<lb/>ated with the use of GLP-1 receptor agonists [69]. Maideen <lb/>and Rashid proposed that healthcare professionals should be <lb/></body>

			<page>978 </page>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/>Sharafshah et al. <lb/></note>

			<body>aware of GLP-1 receptor agonists related to suicidal thoughts <lb/>and self-injurious behavior. Patients should not misuse/abuse <lb/>antidiabetic GLP-1 receptor agonists and should consult their <lb/>physician before using any GLP-1 receptor agonists for <lb/>weight loss [69-76]. <lb/>In contrast, others could not find an association between <lb/>GLP1 agonists and SI or suicide attempts [77-80]. Indeed, <lb/>this is not surprising in terms of our cautionary note concern-<lb/>ing attenuation rather than chronic promotion of enhanced <lb/>dopamine signaling, potentially leading to hypodopaminer-<lb/>gia and potential SI. However, while there is reason for con-<lb/>cern establishing causality requires further investigation, <lb/>which will probably be addressed by the Pharmacovigilance <lb/>Risk Assessment Committee of the European Medicine <lb/>Agency and the FDA in the future, we performed in silico <lb/>pharmacogenomic assessment of GLP1 agonists and GARS <lb/>related pathways to potentially uncover glp1 agonistic in-<lb/>duced suicidality. <lb/>2. METHODS <lb/>The current paper employed a filtering strategy by in-<lb/>cluding candidate genes from various sources, including <lb/>DrugBank <lb/>(https://go.drugbank.com/), <lb/>GeneCards <lb/>(https://www.genecards.org/), and our well-described Genetic <lb/>Addiction Risk Score (GARS) test. The rationale behind <lb/>these sources involved the basic interaction of a medication as <lb/>a ligand (e.g., Ozempic) and potential targets (e.g., receptors); <lb/>accordingly. The initial idea of preparing the primary gene list <lb/>was to consider all of the Ligand/Receptor molecular com-<lb/>pounds based on the curated databases and reliable sources. <lb/>DrugBank is a well-known database in pharmacological sci-<lb/>ences that focuses on FDA-approved compounds. This data-<lb/>base has a Ligand/Receptor nature of data availability. <lb/>GeneCards is a strong, validated, widespread database <lb/>with a genetic focus. Utilizing this databank, we obtained <lb/>highly associated genes with related phenotypes, such as <lb/>Suicide Ideation (SI), based on the relevance score. The the-<lb/>ory behind the relevance score is as follows: Lucene (and <lb/>thus Elasticsearch) employs the Boolean model to identify <lb/>matching documents and a formula called the&quot; practical <lb/>scoring function&quot; to estimate the relevance. This formula <lb/>uses concepts from the term&quot; frequency/inverse document <lb/>frequency and the vector space model. &quot;Still, it adds more <lb/>modern characteristics such as a coordination factor, field <lb/>length normalization, and term or query clause boosting. <lb/>Finally, the GARS gene panel, directly derived from these <lb/>measurable genes and associated risk polymorphisms, is <lb/>known to help identify many psychological/addictive manifes-<lb/>tations. Moreover, since its inception in 2014, the GARS 10 <lb/>gene panel has been shown to predict issues regarding the <lb/>genetic basis of dopamine homeostasis, Substance Use Disor-<lb/>der (SUD), Alcohol Use Disorder (AUD), addiction, and spe-<lb/>cifically, major depression which has been previously docu-<lb/>mented abundant publications (e.g., GWAS) (Table S1). An <lb/>initial list containing 35 genes was found:. After duplication <lb/>filtering, 31 genes remained, and by STRING-MODEL <lb/>(https://string-db.org/) refined to 29 connected genes. By <lb/>NetworkAnalyst <lb/>(https://www.networkanalyst.ca/Network <lb/>Analyst/), Gene-Regulatory Networks (GRNs) carried out in <lb/>Gene-microRNA (miRNA) Interactions (GMIs) based on <lb/>miRTarBase v.8.0. and TF-miRNA coregulatory based on <lb/>RegNetwork repository as sub-analyses. Deep in sili-<lb/>co/enrichment analyses (https://maayanlab.cloud/Enrichr/) <lb/>were performed in three layers: Pathway analysis, Gene On-<lb/>tology (GO), and Disease/Drug analysis. Pathway analysis <lb/>utilized Reactome (https://reactome.org/), Kyoto Encyclopedia <lb/>of Genes and Genomes (KEGG) (https://www.genome.jp/ <lb/>kegg/), and Panther (https://www.pantherdb.org/) databases. <lb/>GO used GO Biological Process, GO Cellular Component, <lb/>and GO Molecular Function; Disease/Drug Analysis em-<lb/>ployed <lb/>DisGENET <lb/>(https://www.disgenet.org/home/), <lb/>GeDiPNet 2023 (http://gedipnet.bicnirrh.res.in/), and Jensen <lb/>DISEASE (https://diseases.jensenlab.org/Search) databases <lb/>(Table 1). <lb/>Along with Table 1, we visualized a flowchart represent-<lb/>ing the process of analysis strategy (Fig. 2). Accordingly, the <lb/>main point in this flowchart is the input data, then refining <lb/>this data by multi-filtration steps, including removing the <lb/>duplicated items and pseudogenes, and reaching multiple <lb/>outputs which are based on the evinced-based clues of <lb/>STRING-MODEL and need future functional validations. Of <lb/>note, further investigations were performed based on the <lb/>connected gene list from PPI, utilizing these refined data <lb/>from the beginning to the end of the analysis. <lb/>3. RESULTS <lb/>3.1. Filtration Strategy and Primary Gene List <lb/>For the filtration process, we employed DrugBank, <lb/>Ozempic (Semaglutide), GLP1R agonist, with four Enzymes <lb/>(DPP4, MME, LPL, and AMY1A) related to GLP1 metabo-<lb/>lism and one carrier in blood plasma albumen (ALB). Based <lb/>on GeneCards score for Suicidal Ideation, the 20 highly <lb/>scored genes were extracted and compared with 10 GARS <lb/>genes (DRD1, DRD2, DRD3, DRD4, MAOA, COMT, <lb/>DAT1 (SLC6A3), SLC6A4, OPRM1, and GABRA3). Re-<lb/>markably, 4 genes of the GARS panel were common in the <lb/>first 20 candidate genes for Suicide Ideation (SI). By com-<lb/>bining the Ozempic target (GLP1R), related enzymes, and <lb/>carrier genes to the 20 best-scored genes and 10 GARS <lb/>genes, 31 genes remained for further analyses. <lb/>3.2. Primary In silico Analyses <lb/>3.2.1. Protein-Protein Interactions (PPIs) <lb/>STRING-MODEL indicated a connected network of 29 <lb/>genes out of 31 primary selected genes (PPI enrichment <lb/>p-value &lt; 1.0e-16). Thus, two unlinked proteins (AMY1A <lb/>and XK) were eliminated. The connected genes are as <lb/>follows: GLP1R, SLC6A4, HTR2A, BDNF-AS, TPH2, <lb/>LOC110806262 (SLC6A4 promoter), BDNF, TPH1, COMT, <lb/>FKBP5, HTR1A, NR3C1, HTR1B, CRH, NTRK2, HTR2C, <lb/>DRD2, IL6, MAOA, CREB1, DRD1, DRD3, DRD4, SLC6A3, <lb/>OPRM1, GABRA3, DPP4, MME and LPL. STRING-<lb/>MODEL shows that GLP1R exhibits strong interactions with <lb/>DRD3, BDNF, CREB1, CRH, IL6, and DPP4 genes (Fig. 3). <lb/>3.2.2. Gene-regulatory Networks (GRNs) <lb/>Employing NetworkAnalyst (https://www.networkanalyst. <lb/>ca/NetworkAnalyst/), GRNs performed in Gene-miRNA In-<lb/>teractions (GMIs) and TF-miRNA revealed coregulation. <lb/></body>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>979 <lb/></page>

			<body>Table 1. Contents, validations, and references of databases and systems biology approaches applied in this paper. <lb/>Level <lb/>Database <lb/>Site <lb/>Software (Version) <lb/>References <lb/>PPIs <lb/>String-Model <lb/>https://string-db.org/ <lb/>STRING (12.0) <lb/>[17] <lb/>GRNs <lb/>GMIs (miRTarBase) <lb/>https://mirtarbase.cuhk.edu.cn <lb/>/~miRTarBase/miRTarBase_2022/php/index.php <lb/>NetworkAnalyst (3.0) <lb/>[18] <lb/>TF-coregulatory Interactions <lb/>http://www.regnetworkweb.org/ <lb/>NetworkAnalyst (3.0) <lb/>[19] <lb/>EA <lb/>Pathway Analysis <lb/>https://maayanlab.cloud/Enrichr/ <lb/>Enrichr <lb/>[20] <lb/>GO <lb/>https://maayanlab.cloud/Enrichr/ <lb/>Enrichr <lb/>[21] <lb/>DDA <lb/>https://maayanlab.cloud/Enrichr/ <lb/>Enrichr <lb/>[22] <lb/>Abbreviations: PPIs: Protein-Protein Interactions; GRNs: Gene Regulatory Networks; GMIs: Gene-miRNA Interactions; EA: Enrichment Analysis; GO: Gene Ontology; and DDA: <lb/>Diseases Drugs Assessment. <lb/>Fig. (2). Flowchart of method strategy in a summarized status. Abbreviations: GARS: Genetic Addiction Risk Severity; PPI: Protein-Protein <lb/>Interaction; GNR: Gene Regulatory Networks; and EA: Enrichment Analysis. (A higher resolution/colour version of this figure is available in <lb/>the electronic copy of the article). <lb/>We also validated GMIs data obtained from miRTarBase <lb/>v.8.0. In a Force Atlas model, GMIs revealed that the <lb/>CREB1 gene is the most interacted seed (betweenness de-<lb/>gree = 107) and hsa-miR-22-3p has the most interactions <lb/>(betweenness degree = 5) among other miRNAs. Interesting-<lb/>ly, GLP1R interacted with CREB1 by hsa-miR-297 and hsa-<lb/>miR-567. Moreover, hsa-miR-204-5p has links with GLP1R, <lb/>CREB1, BDNF, NTRK2, and NR3C1 (Fig. 4). <lb/>For TF-miRNA coregulatory networks, the literature cu-<lb/>rated regulatory interaction information that was collected <lb/>from the RegNetwork repository. In a Linear Bi/Tripartite <lb/>model, the results illustrated in Fig. (5) show the major im-<lb/>pact of CREB1 (1728 interactions), NR3C1 (612 interac-<lb/>tions), NTRK2 (70 interactions), BDNF (67 interactions), <lb/>IL-6 (59 interactions), and SLC6A4 (47 interactions) as the <lb/>best-scored protein targets. Moreover, SP1 and CTCF, both <lb/>with 9 interactions, and REST, with 8 interactions, are the <lb/>most interacted Transcription Factors (TFs). Additionally, <lb/>the most significant miRNAs in this network are hsa-miR-<lb/>16, hsa-miR-22, and hsa-miR-195, all with 6 interactions. <lb/>Interestingly, SP1 and SP3 are TFs that have relationships <lb/>with GLP1R, and OPRM1 has connections with these two <lb/>TFs. <lb/>3.3. Deep In silico Identification through Enrichment <lb/>Analysis <lb/>Enrichment analysis provides deep in silico identifica-<lb/>tion, which was successfully performed on the candidate SI <lb/>gene list suggested in this study. Enrichment analysis was <lb/>categorized into three layers including Pathway Analysis, <lb/>Gene Ontology (GO), and Disease/Drug Analysis. Pathway <lb/>Analysis utilized Reactome, KEGG, and Panther databases. <lb/>GO used GO Biological Process, GO Cellular Component, <lb/>and GO Molecular Function; and Disease/Drug Analysis <lb/>employed DisGENET, GeDiPNet 2023, and JENSEN DIS-<lb/>EASE. <lb/></body>

			<page>980 </page>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/>Sharafshah et al. <lb/></note>

			<body>Fig. (3). STRING-MODEL of PPIs for 31 candidate genes relating to Suicidal Ideation with GARS. (A higher resolution/colour version of <lb/>this figure is available in the electronic copy of the article). <lb/>3.3.1. Pathway Analysis <lb/>According to the Reactome 2022, following Amine Lig-<lb/>and-Binding Receptors R-HSA-375280 (p-value = 5.050e-<lb/>16; adjusted p-value = 8.635e-14; OR = 237.37), Dopamine <lb/>Receptors R-HSA-390651 (p-value =1.780e-11; adjusted <lb/>p-value= 1.096e-9; OR = 3195.20) was the most significant <lb/>pathway based on the 29 candidate genes of SI (Table 2). <lb/>Additionally, in KEGG 2021 HUMAN database classifica-<lb/>tion, after Neuroactive ligand-receptor interaction (p-value = <lb/>4.347e-16; adjusted p-value = 4.869e-14; OR = 48.66) <lb/>and Serotonergic synapse (p-value = 3.139e-12; adjusted <lb/>p-value = 1.758e-10; OR = 72.08), the Dopaminergic syn-<lb/>apse was in third place with a p-value of 1.110e-11, an ad-<lb/>justed p-value of 4.143e-10, and an OR of 60.97; thus, the <lb/>significance of Dopaminergic synapse was not very different <lb/>from the significance of Serotonergic synapses (adjusted <lb/>p-value = 1.758e-10) (Table 3). Finally, PANTHER listed <lb/>the Dopamine receptor-mediated signaling pathway Homo <lb/>sapiens P05912 as the most significant pathway (p-value = <lb/>1.040e-10; adjusted p-value = 1.768e-9; and OR = 113) for <lb/>the gene list (Table 4). Altogether, Pathway Analysis provid-<lb/>ed strong evidence for dopamine signaling in the SI pheno-<lb/>type. <lb/></body>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>981 <lb/></page>

			<body>Fig. (4). Force Atlas model of GMIs for 29 candidate genes including GARS genes representing CREB1 and hsa-miR-22-3p as the most in-<lb/>teracting seed and miRNA, respectively. (A higher resolution/colour version of this figure is available in the electronic copy of the article). <lb/>Table 2. Reactome 2022 results for pathway analysis of 21 candidate genes list related to suicide ideation. <lb/>Index <lb/>Name <lb/>P-value <lb/>q-value <lb/>OR <lb/>1 <lb/>Amine Ligand-Binding Receptors R-HSA-375280 <lb/>5.050e-16 <lb/>8.635e-14 <lb/>237.37 <lb/>2 <lb/>Dopamine Receptors R-HSA-390651 <lb/>1.780e-11 <lb/>1.096e-9 <lb/>3195.20 <lb/>3 <lb/>GPCR Ligand Binding R-HSA-500792 <lb/>1.923e-11 <lb/>1.096e-9 <lb/>26.69 <lb/>4 <lb/>Signaling By GPCR R-HSA-372790 <lb/>7.703e-11 <lb/>3.293e-9 <lb/>20.12 <lb/>5 <lb/>Class A/1 (Rhodopsin-like Receptors) R-HSA-373076 <lb/>5.619e-10 <lb/>1.922e-8 <lb/>27.81 <lb/>6 <lb/>Neurotransmitter Clearance R-HSA-112311 <lb/>7.437e-10 <lb/>2.120e-8 <lb/>532.40 <lb/>7 <lb/>Serotonin Receptors R-HSA-390666 <lb/>1.168e-9 <lb/>2.852e-8 <lb/>456.32 <lb/>8 <lb/>Signal Transduction R-HSA-162582 <lb/>3.963e-9 <lb/>8.470e-8 <lb/>10.14 <lb/>9 <lb/>GPCR Downstream Signaling R-HSA-388396 <lb/>8.833e-9 <lb/>1.678e-7 <lb/>16.73 <lb/>10 <lb/>Transcriptional Regulation By MECP2 R-HSA-8986944 <lb/>2.303e-8 <lb/>3.938e-7 <lb/>75.44 <lb/>Note: OR refers to Odds ration and q-value is calculated based on adjusted p-value. <lb/></body>

			<page>982 </page>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/> Sharafshah et al. <lb/></note>

			<body>Fig. (5). The Linear Bi/Tripartite model is built on the TF-miRNA coregulatory network of 29 SI candidate genes. According to this figure, <lb/>CREB1, SP1, and miR-16 and -22 are the most important protein targets, TF, and miRNAs, respectively. (A higher resolution/colour version <lb/>of this figure is available in the electronic copy of the article). <lb/>Table 3. KEGG HUMAN 2021 phenotypes resulted from 29 candidate genes. <lb/>Index <lb/>Name <lb/>P-value <lb/>q-value <lb/>OR <lb/>1 <lb/>Neuroactive ligand-receptor interaction <lb/>4.347e-16 <lb/>4.869e-14 <lb/>48.66 <lb/>2 <lb/>Serotonergic synapse <lb/>3.139e-12 <lb/>1.758e-10 <lb/>72.08 <lb/>3 <lb/>Dopaminergic synapse <lb/>1.110e-11 <lb/>4.143e-10 <lb/>60.97 <lb/>4 <lb/>Cocaine addiction <lb/>7.166e-11 <lb/>2.006e-9 <lb/>120.90 <lb/>5 <lb/>Alcoholism <lb/>1.747e-10 <lb/>3.914e-9 <lb/>42.36 <lb/>6 <lb/>cAMP signaling pathway <lb/>1.983e-8 <lb/>3.702e-7 <lb/>30.09 <lb/>7 <lb/>Amphetamine addiction <lb/>0.000002887 <lb/>0.00004619 <lb/>49.00 <lb/>8 <lb/>Gap junction <lb/>0.000007640 <lb/>0.0001070 <lb/>37.88 <lb/>9 <lb/>Tryptophan metabolism <lb/>0.00003029 <lb/>0.0003769 <lb/>58.97 <lb/>10 <lb/>Taste transduction <lb/>0.0002587 <lb/>0.002897 <lb/>27.65 <lb/>Note: OR means Odds Ration and q-value stands for adjusted p-value. <lb/></body>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>983 <lb/></page>

			<body>Table 4. PANTHER pathways for candidate gene list of SI. <lb/>Index <lb/>Name <lb/>P-value <lb/>q-value <lb/>OR <lb/>1 <lb/>Dopamine receptor mediated signaling pathway Homo sapiens P05912 <lb/>1.040e-10 <lb/>1.768e-9 <lb/>113.00 <lb/>2 <lb/>Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway <lb/>Homo sapiens P00026 <lb/>2.453e-8 <lb/>2.085e-7 <lb/>42.80 <lb/>3 <lb/>Adrenaline and noradrenaline biosynthesis Homo sapiens P00001 <lb/>0.000006170 <lb/>0.00003496 <lb/>104.63 <lb/>4 <lb/>5HT1 type receptor mediated signaling pathway Homo sapiens P04373 <lb/>0.000009764 <lb/>0.00004150 <lb/>88.51 <lb/>5 <lb/>5HT2 type receptor mediated signaling pathway Homo sapiens P04374 <lb/>0.00003990 <lb/>0.0001356 <lb/>53.47 <lb/>6 <lb/>Enkephalin release Homo sapiens P05913 <lb/>0.0002724 <lb/>0.0007718 <lb/>98.55 <lb/>7 <lb/>Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated path-<lb/>way Homo sapiens P00027 <lb/>0.0004783 <lb/>0.001162 <lb/>22.26 <lb/>8 <lb/>Nicotine pharmacodynamics pathway Homo sapiens P06587 <lb/>0.0007496 <lb/>0.001593 <lb/>56.82 <lb/>9 <lb/>5-Hydroxytryptamine degradation Homo sapiens P04372 <lb/>0.007230 <lb/>0.01366 <lb/>178.28 <lb/>10 <lb/>5HT3 type receptor mediated signaling pathway Homo sapiens P04375 <lb/>0.02296 <lb/>0.03548 <lb/>47.51 <lb/>Note: q-value is computated based on adjusted p-value and OR refers to Odds Ration. <lb/>Table 5. List of genes associated with suicide ideation (based on GO biological process database, 2023). <lb/>Index <lb/>Name <lb/>P-value <lb/>q-value <lb/>OR <lb/>1 <lb/>Dopamine Metabolic Process (GO:0042417) <lb/>1.432e-13 <lb/>7.174e-11 <lb/>400.49 <lb/>2 <lb/>G Protein-Coupled Receptor (GPCR) Signaling Pathway, (GO:0007187) <lb/>5.893e-13 <lb/>1.476e-10 <lb/>147.46 <lb/>3 <lb/>Catecholamine Metabolic Process (GO:0006584) <lb/>5.687e-12 <lb/>9.497e-10 <lb/>519.87 <lb/>4 <lb/>Adenylate Cyclase-Inhibiting GPCR Signaling Pathway (GO:0007193) <lb/>1.040e-10 <lb/>1.303e-8 <lb/>113.00 <lb/>5 <lb/>GPCR Serotonin Signaling Pathway (GO:0098664) <lb/>4.467e-10 <lb/>4.476e-8 <lb/>638.91 <lb/>6 <lb/>Phospholipase C-mediated Signaling Pathway (GO:0007200) <lb/>1.870e-9 <lb/>1.562e-7 <lb/>67.40 <lb/>7 <lb/>Chemical Synaptic Transmission (GO:0007268) <lb/>3.642e-9 <lb/>2.607e-7 <lb/>28.33 <lb/>8 <lb/>Response To Organonitrogen Compound (GO:0010243) <lb/>6.552e-9 <lb/>4.103e-7 <lb/>98.85 <lb/>9 <lb/>Response to Ethanol (GO:0045471) <lb/>1.075e-8 <lb/>5.985e-7 <lb/>228.08 <lb/>10 <lb/>Behavioral Fear Response (GO:0001662) <lb/>2.735e-8 <lb/>0.000001246 <lb/>1152.06 <lb/>Abbreviations: GO: Gene Ontology; q-value: adjusted p-value; and OR: Odds Ratio. <lb/>3.3.2. GO Analyses <lb/>Deep in silico/enrichment analyses based on GO Biologi-<lb/>cal Process showed Dopaminergic Signaling (GO:0042417, <lb/>p-value of 1.432e-13, adjusted p-value of 7.174e-11, and OR <lb/>of 400.49) as the most associated with the SI phenotype <lb/>(Table 5). Analysis of GO Cellular Component 2023 indicat-<lb/>ed that Neuron Projection (GO:0043005, p-value of 7.589e-<lb/>15, adjusted p-value of 2.656e-13, and OR of 33.39) is close-<lb/>ly related to the SI phenotype (Table 6). Moreover, Serotonin <lb/>G Protein-Coupled Receptor Activity (GO:0004993) is the <lb/>top-list of GO Molecular Function 2023 assessment (p-value <lb/>= 8.920e-11; adjusted p-value = 6.779e-9; and OR = 259.83) <lb/>(Table 7). These findings support the idea that RDS and SI <lb/>may share common mechanisms. <lb/>3.3.3. Disease Drugs Interaction Analysis (DDA) <lb/>DDA was conducted by three databases: DisGeNET, <lb/>GeDiPNet 2023, and JENSEN DISEASE, and their results <lb/>are summarized in Table 8. According to these results, the <lb/>most significant disease phenotype was Major depressive <lb/>disorder defined by Jensen DISEASE (p-value = 4.01E-40; <lb/>adjusted p-value = 6.54e-38; and OR = 630.51) followed by <lb/>Substance abuse (p-value = 2.20E-35; adjusted p-value = <lb/>1.80e-33; and OR = 681.54) and Alcohol dependence <lb/>(p-value = 4.46E-35; adjusted p-value= 2.42e-33; and OR= <lb/>382.83). Noteworthy, the best models of DisGeNET and <lb/>GeDiPNet 2023 were Mental depression (p-value = 3.72E-35; <lb/>adjusted p-value = 9.12e-32; and OR = 220.69) and Mood <lb/>disorder (p-value = 1.09E-31; adjusted p-value = 3.69E-29; <lb/>and OR = 163.8), respectively (Table 8). <lb/>To get a better view, Scatter plots, Manhattan plots, and <lb/>Volcano plots for the Jensen DISEASE and DisGeNET are <lb/>illustrated in Figs. (6, 7, and 8). The scatterplot was organized <lb/>so that similar gene sets were clustered together. Larger, <lb/>black-outlined points indicate significantly enriched terms. In <lb/>the Manhattan plot, each line on the x-axis denoted a single <lb/>gene set from the selected library, while the y-axis measured <lb/>the -log 10 (p-value) for each gene set. The volcano plot shows <lb/>the significance of each gene set from the designated library <lb/></body>

			<page>984 </page>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/>Sharafshah et al. <lb/></note>

			<body>Table 6. Results of GO cellular component 2023 for SI candidate gene list. <lb/>Index <lb/>Name <lb/>P-value <lb/>q-value <lb/>OR <lb/>1 <lb/>Neuron Projection (GO:0043005) <lb/>7.589e-15 <lb/>2.656e-13 <lb/>33.39 <lb/>2 <lb/>Dendrite (GO:0030425) <lb/>6.176e-14 <lb/>1.081e-12 <lb/>46.51 <lb/>3 <lb/>Axon (GO:0030424) <lb/>4.206e-7 <lb/>0.000004906 <lb/>25.92 <lb/>4 <lb/>Non-Motile Cilium (GO:0097730) <lb/>0.0008611 <lb/>0.007535 <lb/>52.76 <lb/>5 <lb/>Ciliary Membrane (GO:0060170) <lb/>0.001382 <lb/>0.009672 <lb/>41.02 <lb/>6 <lb/>Membrane Raft (GO:0045121) <lb/>0.001843 <lb/>0.01075 <lb/>13.77 <lb/>7 <lb/>Flotillin Complex (GO:0016600) <lb/>0.008670 <lb/>0.04335 <lb/>142.61 <lb/>8 <lb/>Cell Projection Membrane (GO:0031253) <lb/>0.01011 <lb/>0.04421 <lb/>14.29 <lb/>9 <lb/>Focal Adhesion (GO:0005925) <lb/>0.01810 <lb/>0.06685 <lb/>5.89 <lb/>10 <lb/>Cell-Substrate Junction (GO:0030055) <lb/>0.01910 <lb/>0.06685 <lb/>5.76 <lb/>Note: GO and OR stand for Gene ontology and Odds Ratio, respectively. <lb/>Table 7. The categorized list of GO Molecular Function 2023 for candidate gene list involving in SI. <lb/>Index <lb/>Name <lb/>P-value <lb/>q-value <lb/>OR <lb/>1 <lb/>GPCR Serotonin Activity (GO:0004993) <lb/>8.920e-11 <lb/>6.779e-9 <lb/>259.83 <lb/>2 <lb/>Serotonin Receptor Activity (GO:0099589) <lb/>2.869e-10 <lb/>1.084e-8 <lb/>197.92 <lb/>3 <lb/>G Protein-Coupled Amine Receptor Activity (GO:0008227) <lb/>4.278e-10 <lb/>1.084e-8 <lb/>180.69 <lb/>4 <lb/>Monoamine Transmembrane Transporter Activity (GO:0008504) <lb/>0.0001108 <lb/>0.002104 <lb/>164.30 <lb/>5 <lb/>Sodium:Chloride Symporter Activity (GO:0015378) <lb/>0.0001568 <lb/>0.002383 <lb/>134.41 <lb/>6 <lb/>Postsynaptic Neurotransmitter Receptor Activity (GO:0098960) <lb/>0.0003419 <lb/>0.004330 <lb/>86.95 <lb/>7 <lb/>GPCR Activity (GO:0004930) <lb/>0.0004427 <lb/>0.004806 <lb/>12.83 <lb/>8 <lb/>Receptor Ligand Activity (GO:0048018) <lb/>0.001101 <lb/>0.01046 <lb/>9.98 <lb/>9 <lb/>Exopeptidase Activity (GO:0008238) <lb/>0.002574 <lb/>0.02173 <lb/>29.51 <lb/>10 <lb/>Growth Factor Activity (GO:0008083) <lb/>0.006727 <lb/>0.04118 <lb/>17.75 <lb/>Abbreviations: GPCR: G-protein Coupled Receptor; GO: Gene Ontology; OR: Odds Ratio. <lb/>Table 8. Candidate genes of SI phenotype (29 genes) extracted from combined results from DisGeNET, GeDiPNET, and JENSEN <lb/>DISEASE databases. <lb/>Index <lb/>Name <lb/>Database <lb/>P-value <lb/>q-value <lb/>OR <lb/>1 <lb/>Major Depressive Disorder <lb/>JENSEN DISEASE <lb/>4.01E-40 <lb/>6.54E-38 <lb/>630.51 <lb/>2 <lb/>Substance Abuse <lb/>JENSEN DISEASE <lb/>2.20E-35 <lb/>1.80E-33 <lb/>681.54 <lb/>3 <lb/>Alcohol Dependence <lb/>JENSEN DISEASE <lb/>4.46E-35 <lb/>2.42E-33 <lb/>382.83 <lb/>4 <lb/>Mental Depression <lb/>DisGeNET <lb/>3.72E-35 <lb/>9.12E-32 <lb/>220.69 <lb/>5 <lb/>Mental Disorders <lb/>DisGeNET <lb/>3.94E-34 <lb/>3.32E-31 <lb/>201.31 <lb/>6 <lb/>Major Depressive Disorder <lb/>DisGeNET <lb/>4.06E-34 <lb/>3.32E-31 <lb/>191.23 <lb/>7 <lb/>Drug Abuse <lb/>DisGeNET <lb/>5.88E-33 <lb/>3.61E-30 <lb/>210.12 <lb/>8 <lb/>Depressive Disorder <lb/>DisGeNET <lb/>2.30E-32 <lb/>1.05E-29 <lb/>168.08 <lb/>9 <lb/>Anxiety Disorders <lb/>DisGeNET <lb/>2.58E-32 <lb/>1.05E-29 <lb/>164.68 <lb/>10 <lb/>Unipolar Depression <lb/>DisGeNET <lb/>7.76E-32 <lb/>2.72E-29 <lb/>151.14 <lb/>11 <lb/>Mood Disorders <lb/>DisGeNET <lb/>1.09E-31 <lb/>3.25E-29 <lb/>163.8 <lb/>(Table 8) Contd…. <lb/></body>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>985 <lb/></page>

			<body>Index <lb/>Name <lb/>Database <lb/>P-value <lb/>q-value <lb/>OR <lb/>12 <lb/>Alcoholic Intoxication, Chronic <lb/>DisGeNET <lb/>1.19E-31 <lb/>3.25E-29 <lb/>152.99 <lb/>13 <lb/>Cocaine Dependence <lb/>DisGeNET <lb/>1.51E-31 <lb/>3.69E-29 <lb/>233.47 <lb/>14 <lb/>Mood Disorder <lb/>GeDiPNet <lb/>1.65E-31 <lb/>6.38E-29 <lb/>176.01 <lb/>15 <lb/>Bipolar Disorder <lb/>GeDiPNet <lb/>7.60E-27 <lb/>1.47E-24 <lb/>89.84 <lb/>16 <lb/>Mental Depression <lb/>GeDiPNet <lb/>4.79E-26 <lb/>6.18E-24 <lb/>83.8 <lb/>17 <lb/>Personality Disorder <lb/>JENSEN DISEASE <lb/>4.82E-20 <lb/>1.97E-18 <lb/>472.55 <lb/>18 <lb/>Schizophrenia <lb/>GeDiPNet <lb/>3.34E-18 <lb/>3.23E-16 <lb/>33.53 <lb/>19 <lb/>Obsessive-compulsive Disorder <lb/>JENSEN DISEASE <lb/>9.18E-17 <lb/>2.99E-15 <lb/>303.94 <lb/>20 <lb/>Post-traumatic Stress Disorder <lb/>JENSEN DISEASE <lb/>3.22E-16 <lb/>8.74E-15 <lb/>253.22 <lb/>21 <lb/>Jacksonian Seizure <lb/>GeDiPNet <lb/>1.37E-14 <lb/>1.06E-12 <lb/>97.23 <lb/>22 <lb/>Dementia <lb/>JENSEN DISEASE <lb/>6.23E-14 <lb/>1.45E-12 <lb/>81.25 <lb/>23 <lb/>Clonic Seizures <lb/>GeDiPNet <lb/>5.33E-14 <lb/>3.44E-12 <lb/>82.76 <lb/>24 <lb/>Heroin Dependence <lb/>JENSEN DISEASE <lb/>2.86E-13 <lb/>5.82E-12 <lb/>347.06 <lb/>25 <lb/>Gilles de la Tourette Syndrome <lb/>JENSEN DISEASE <lb/>4.35E-13 <lb/>7.88E-12 <lb/>154.67 <lb/>26 <lb/>Hypotonic Seizures <lb/>GeDiPNet <lb/>2.42E-13 <lb/>1.34E-11 <lb/>69.22 <lb/>27 <lb/>Nicotine Dependence <lb/>JENSEN DISEASE <lb/>9.07E-13 <lb/>1.48E-11 <lb/>137.82 <lb/>28 <lb/>Anhedonia <lb/>GeDiPNet <lb/>7.07E-13 <lb/>3.42E-11 <lb/>289.17 <lb/>29 <lb/>Manic Disorder <lb/>GeDiPNet <lb/>1.66E-11 <lb/>7.15E-10 <lb/>87.94 <lb/>30 <lb/>Melancholia <lb/>GeDiPNet <lb/>2.32E-11 <lb/>8.99E-10 <lb/>148.59 <lb/>Note: q-value and OR refer to adjusted p-value and Odds Ratio, respectively. <lb/>versus its odds ratio. Each point displays a single Geneset; <lb/>the x-axis measures the odds ratio (0, inf) calculated for the <lb/>gene set, while the y-axis yields the -log(p-value) of the gene <lb/>set. Larger blue points represent significant terms (p-value &lt; <lb/>0.05); smaller gray points indicate non-significant terms. Also, <lb/>the darker the blue color of a point, the more important it is. <lb/>4. DISCUSSION <lb/>In summary, by employing comprehensive in silico anal-<lb/>ysis, this study revealed genetic associations and close inter-<lb/>action between GLP1 signaling and specifically GLP1 recep-<lb/>tor with 29 refined genes through STRING-MODEL, espe-<lb/>cially with DRD3, BDNF, CREB1, CRH, IL6, and DPP4 <lb/>genes. GMIs revealed that the CREB1 gene is the most asso-<lb/>ciated seed, and hsa-miR-22-3p has the most interactions <lb/>among other miRNAs. Interestingly, GLP1R was associated <lb/>with CREB1 through hsa-miR-297 and hsa-miR-567. More-<lb/>over, hsa-miR-204-5p has connections with GLP1R, <lb/>CREB1, BDNF, NTRK2, and NR3C1. TF-miRNA coregula-<lb/>tory networks showed the major impact of CREB1, NR3C1, <lb/>NTRK2, BDNF, IL-6, and SLC6A4 as the best-scored pro-<lb/>tein targets. Furthermore, SP1 and CTCF were the most in-<lb/>terconnected TFs. Additionally, hsa-miR-16, hsa-miR-22, <lb/>and hsa-miR-195 were found to be the most significant asso-<lb/>ciated miRNAs in this network. Curiously, SP1 and SP3 <lb/>were linked with GLP1R and OPRM1. According to the <lb/>Pathways analyses, Dopamine Receptors R-HSA-390651, <lb/>Dopaminergic synapse, and Dopamine receptor-mediated <lb/>signaling pathway Homo sapiens P05912 were found as the <lb/>top associate candidates. GO analyses showed Dopamine <lb/>Metabolic Process (GO:0042417), Neuron Projection <lb/>(GO:0043005), and G Protein-Coupled Serotonin Receptor <lb/>Activity (GO:0004993) as the most significant processes. <lb/>The most significant associated disease-causing phenotype <lb/>among all three databases was major depressive disorder. <lb/>Substance abuse and alcohol dependence were the second <lb/>and third. Noteworthy, the best models of DisGeNET and <lb/>GeDiPNet 2023 were both mental depression and mood dis-<lb/>orders. <lb/>As mentioned earlier, a comprehensive gene list contain-<lb/>ing 29 genes was refined during a strategy of filtering the SI <lb/>construct. These genes are included in the filtration accord-<lb/>ing to the pharmacological and ligand-target interactions of <lb/>Ozempic as the agonist of GLP1R and, three other enzymes <lb/>and one plasma blood carrier. Additionally, we found the top <lb/>20 best-scored genes in GeneCards for &quot;Suicide Ideation&quot; as <lb/>a keyword, including the 10 genes of GARS. Multiple anal-<lb/>yses of these genes, including PPIs, GMIs, and TF-miR as a <lb/>coregulatory network, revealed interesting results. Specifi-<lb/>cally, a deep in silico study of Enrichment Analysis was suc-<lb/>cessfully carried out for this gene list. Pathway Analysis, GO <lb/>analysis, and Disease Drug Analysis (DDA) all indicated that <lb/>depressive phenotypes and dopamine regulation are the most <lb/>significant associated factors playing remarkable roles in SI. <lb/>Importantly, we caution against GLP1 agonist administra-<lb/>tion, especially in patients with known hypodopaminergia, <lb/>rather than its general approval for long-term addiction <lb/>treatment. However, our results were based on strong evi-<lb/>dence and clinical reports in previous studies. Further clini-<lb/>cal confirmation is required, and we acknowledge that the <lb/>connection between neural transmission changes and SI re-<lb/>mains speculative and multifactorial. <lb/></body>

			<page>986</page>
			
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/>Sharafshah et al. <lb/></note>

			<body>Fig. (6). Scatterplot of all terms in Jensen Disease database (A) and DisGeNET database (B). Each point signifies a term in the library. Term <lb/>frequency-inverse document frequency (TF-IDF) values were computed for the gene set corresponding to each term, and UMAP was utilized <lb/>to display the resulting values. The terms are plotted based on the first two UMAP dimensions. Generally, terms with more similar gene sets <lb/>are positioned closer together. Terms are colored by automatically identified clusters computed with the Leiden algorithm applied to the <lb/>TF-IDF values. The darker and larger the point, the more significantly enriched the term. Hovering over points will display the term, the <lb/>p-value from the enrichment calculation, and the automatically assigned cluster. (A higher resolution/colour version of this figure is available <lb/>in the electronic copy of the article). <lb/>(A) <lb/>(B) <lb/></body>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>987 <lb/></page>

			<body>Fig. (7). Manhattan plot of terms from Jensen Disease database (A) and DisGeNET database (B) for SI candidate gene list indicating Depres-<lb/>sion as the most top hub. Each point represents a single term along the x-axis. The y-values represent the -log10(p-value) corresponding to the <lb/>enrichment of the input gene set for the term gene set. (A higher resolution/colour version of this figure is available in the electronic copy of <lb/>the article). <lb/>(Fig. 8) Contd…. <lb/>(A) <lb/>(B) <lb/>(A) <lb/></body>

			<page>988</page>

			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/>Sharafshah et al. <lb/></note>

			<body>Fig. (8). Volcano plot of terms from Jensen Disease database (A) and DisGeNET database (B) for SI candidate gene list showing depression <lb/>phenotype in the top. Each point shows a single term, plotted by the corresponding odds ratio (x-position) and -log10(p-value) (y-position) <lb/>from the enrichment results of the input query gene set. The larger and darker-colored the point, the more significantly enriched the input <lb/>gene set is for the term. (A higher resolution/colour version of this figure is available in the electronic copy of the article). <lb/>The majority of studies to date have indeed reported the <lb/>benefits of Ozempic consumption. However, our study from <lb/>a genetic standpoint indicated inconsistent findings. It is not <lb/>possible to compare our studies with all of the reports due to <lb/>some glaring reasons; this is not a review article, and we <lb/>introduced a new perspective that requires further validation <lb/>and confirmation. The FDA reported that they did not find an <lb/>association between the use of the GLP-1 variant and suicid-<lb/>al thoughts or actions. However, they could not definitively <lb/>rule out that a small risk may exist. <lb/>Despite these initial findings, we urge caution concerning <lb/>attenuation rather than the chronic promotion of enhanced <lb/>dopamine signaling, potentially leading to hypodopaminer-<lb/>gic. Most recently, Wang et al., in a real-world cohort rely-<lb/>ing on electronic records, compared GLP1 agonistic therapy <lb/>like semaglutide with other non-GLP1 agonist weight loss <lb/>agents for depression and SI and could not support a rela-<lb/>tionship of induction of depression and SI for semaglutide <lb/>[79]. While we are not refuting this important work by Wang <lb/>et al. [79], albeit the issue whereby electronic records of pa-<lb/>tients may yield omissions related to certain diagnostic crite-<lb/>ria (e.g., SI and even suicide attempts), we cannot ignore <lb/>media reports such as the April 17 th from the NY Post sug-<lb/>gesting that Ozempic appears to be changing a growing <lb/>number of patients claiming that the GLP1 agonistic medica-<lb/>tions have caused anxiety, and SI even as they shed the <lb/>pounds. It is also well-known that obese individuals also <lb/>have a reduced dopaminergic function either genetically [24] <lb/>or epigenetically [25], which only further complicates the <lb/>issue at hand. However, it is indeed noteworthy that while <lb/>we are in no position to assess the accuracy of the data col-<lb/>lected from archival EMRs used in the Wang et al. study <lb/>[79], there exists a plethora of literature reports (PubMed; <lb/>Assessed 4-20-2024; 51,395 listings using EMR as a word <lb/>search) that argue and or question the validity of utilizing <lb/>EMR for assessing clinical outcomes and important ques-<lb/>tions [26-30]. Specifically, the secondary use of clinical data <lb/>for research purposes is not without limitations. In accord-<lb/>ance with the Preferred Reporting Items for Systematic Re-<lb/>views and Meta-Analyses guidelines, Edmondson &amp; Reimer <lb/>[31] performed a systematic review to identify current issues <lb/>related to the secondary use of electronic medical record data <lb/>via MEDLINE and CINAHL databases. All articles pub-<lb/>lished until June 2018 were included. Sixty articles remained <lb/>after title and abstract review, and four domains of potential <lb/>limitations were identified: (1) data quality issues, present in <lb/>91.7% of the articles reviewed; (2) data preprocessing chal-<lb/>lenges (53.3%); (3) privacy concerns (18.3%); and (4) poten-<lb/>tial for limited generalizability (21.7%). <lb/>Diabetes and insulin resistance are associated with al-<lb/>tered brain imaging, depression, and increased rates of age-<lb/>related cognitive impairment. Importantly, it has been <lb/>(B) <lb/></body>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>989 <lb/></page>

			<body>demonstrated that mice with a brain-specific knockout of the <lb/>insulin receptor (Neuronal Insulin Receptor Knockout <lb/>(NIRKO) mice) exhibit brain mitochondrial dysfunction with <lb/>reduced mitochondrial oxidative activity, increased levels of <lb/>reactive oxygen species, and increased levels of lipid and <lb/>protein oxidation in the striatum and nucleus accumbens [81, <lb/>82]; NIRKO mice also exhibit increased levels of monoam-<lb/>ine oxidase A and B (MAO A and B) leading to increased <lb/>dopamine turnover in these areas. This finding may exacer-<lb/>bate people with a genetic predisposition for schizophrenia, <lb/>whereby reduced dopamine availability in the mitochondria <lb/>could affect the clinical presence of schizophrenia and even <lb/>depression [83, 84]. Studies in cultured neurons and glial <lb/>cells indicate that these changes in MAO A and B are a di-<lb/>rect consequence of loss of insulin signaling [85, 86]. As a <lb/>result, NIRKO mice develop age-related anxiety and depres-<lb/>sive-like behaviors that can be reversed by treatment with <lb/>MAO inhibitors, as well as the tricyclic antidepressant imi-<lb/>pramine, which inhibits MAO activity and reduces oxidative <lb/>stress [87]. Also, insulin resistance in the brain induces mito-<lb/>chondrial and dopaminergic dysfunction, leading to anxiety <lb/>and depressive-like behaviors, demonstrating a potential <lb/>molecular link between central insulin resistance and behav-<lb/>ioral disorders [88]. Another limitation arises from the con-<lb/>troversy of various clinical reports related to this important <lb/>topic. Interestingly, following careful consideration of the <lb/>literature for investigating any match results with ours, we <lb/>found a recent animal study by Sadek et al. conducted on the <lb/>plausible impact of semaglutide on experimental autoim-<lb/>mune encephalomyelitis (EAE)-induced Multiple sclerosis in <lb/>mice. They found semaglutide triggers the PI3K/Akt axis, <lb/>which, in turn, inhibits the activity of GSK-3β. The inhibited <lb/>GSK3β activity then decreases demyelination and causes <lb/>remyelination via CREB/BDNF; moreover, it increases Nrf2 <lb/>and SOD levels leading to protection in mice from EAE-<lb/>induced oxidative stress [89]. A recently published report by <lb/>Schoretsanitis et al. utilized the WHO database and found an <lb/>association of Ozempic with suicidal ideation, which con-<lb/>firms our results [90]. <lb/>5. LIMITATIONS <lb/>The current study has some limitations. For example, <lb/>there is a lack of functional and molecular validation related <lb/>to the link between pharmacological GLPR1 activation, de-<lb/>pressive behavior, and SI. We utilized well-known sources <lb/>with high reliability in our in silico and systems biology <lb/>analyses, which might be augmented with additional sources <lb/>or new sources in similar future studies. Another limitation <lb/>in silico analysis is considered reporting every detail in fu-<lb/>ture studies and neglecting the priorities (we basically re-<lb/>ported the priorities/top-scored results). Additionally, tran-<lb/>scriptomics and GWAS studies regarding Ozempic or other <lb/>GLP1R agonists are limited; thus, our transcriptomic-<lb/>associated results (potential miRNAs and Transcription Fac-<lb/>tors) remarkably need further validation on clinical samples. <lb/>Our finding in the PPI network for BDNF should be further <lb/>investigated in future genetic studies [91], as well as adverse <lb/>effects, especially in terms of depression and RDS behaviors <lb/>[92, 93]. <lb/>CONCLUSION <lb/>Despite the FDA&apos;s recent remarks that SI associated with <lb/>GLP1R agonism is not a concern, these findings obviously <lb/>show the negative impact of Ozempic as an agonist for <lb/>GLP1 and its receptor (GLP1R). When Ozempic reaches the <lb/>blood, it will begin to induce a number of reactions starting <lb/>from GLP1 and its receptor. Based on our silico predictions, <lb/>the binding of Ozempic to GLP1 receptor will activate sev-<lb/>eral pathways, which may lead to the dysregulation of the <lb/>dopaminergic signaling and, as a consequence, exacerbation <lb/>of depressive behaviors, which are one of the main endophe-<lb/>notypes of RDS. Notably, the associations found in the in <lb/>silico analysis require further empirical validation through <lb/>clinical studies. <lb/></body>
				
			<div type="annex">AUTHORS&apos; CONTRIBUTIONS <lb/>Conceptualization, A.S., K.L.; Writing-original draft <lb/>preparation, A.S., K.L., K.B.; Writing-review and editing, <lb/>A.S., K.L., M.S.G., B.F., J.W.A., P.K.T., G.J.W., C.H., <lb/>J.L.C., E.L.G., J.H.K, E.R.B., D.B., I.E., C.A.D., A.B., AP., <lb/>E.J.M., P.R.C., R.C., R.K.A.F., S.S., A.R.P., K.B. and <lb/>R.D.B. All authors have read and agreed to the published <lb/>version of the manuscript. <lb/>LIST OF ABBREVIATIONS <lb/>GLP1R = Glucagon-like peptide-1 Receptor <lb/>SUD <lb/>= Substance Use Disorder <lb/>AUD <lb/>= Alcohol Use Disorder <lb/>SI <lb/>= Suicidal Ideation <lb/>RDS <lb/>= Reward Deficiency Syndrome <lb/>VTA <lb/>= Ventral Tegmental Area <lb/>NAc <lb/>= Nucleus Accumbens <lb/>GLP-1 <lb/>= Glucagon-like Peptide 1 <lb/>ASCVD = Atherosclerotic Cardiovascular Disease <lb/>fMRI <lb/>= Functional MRI <lb/>GO <lb/>= Gene Ontology <lb/>SI <lb/>= Suicide Ideation <lb/>PPIs <lb/>= Protein-protein Interactions <lb/>GRNs <lb/>= Gene-regulatory Networks <lb/>DDA <lb/>= Disease Drug Analysis <lb/>ETHICS APPROVAL AND CONSENT TO PARTICI-<lb/>PATE <lb/>Not applicable. <lb/>HUMAN AND ANIMAL RIGHTS <lb/>Not applicable. <lb/>CONSENT FOR PUBLICATION <lb/>Not applicable. <lb/></div>

			<page>990 </page>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/>Sharafshah et al. <lb/></note>

			<div type="availability">AVAILABILITY OF DATA AND MATERIALS <lb/>The data and supportive information are available within <lb/>the article. <lb/></div>

			<div type="funding">FUNDING <lb/>None. <lb/></div>

			<div type="annex">CONFLICT OF INTEREST <lb/>Dr. Jean Lud Cadet is on the Editorial Advisory Board of <lb/>the journal Current Neuropharmacology. <lb/></div>

			<div type="acknowledgement">ACKNOWLEDGEMENTS <lb/>Declared none. <lb/></div>

			<div type="annex">SUPPLEMENTARY MATERIAL <lb/>Supplementary material is available on the publisher&apos;s <lb/>website along with the published article. <lb/></div>

			<listBibl>REFERENCES <lb/>[1] <lb/>Abuse, S.; Administration, M.H.S. Key substance use and mental <lb/>health indicators in the United States: Results from the 2018 <lb/>National survey on drug use and health. 2019. Available <lb/>from: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/ <lb/>NSDUHNationalFindingsReport2018/NSDUHNationalFindings <lb/>Report2018.htm <lb/>[2] <lb/>Organization, W.H. Global status report on road safety 2018; <lb/>World Health Organization, 2019. <lb/>[3] <lb/>Kohn, R.; Saxena, S.; Levav, I.; Saraceno, B. The treatment gap in <lb/>mental health care. Bull. World Health Organ., 2004, 82(11), 858-<lb/>866. <lb/>PMID: 15640922 <lb/>[4] <lb/>Dahlgren, A.; Wargelius, H.L.; Berglund, K.J.; Fahlke, C.; Blen-<lb/>now, K.; Zetterberg, H.; Oreland, L.; Berggren, U.; Balldin, J. Do <lb/>alcohol-dependent individuals with DRD2 A1 allele have an in-<lb/>creased risk of relapse? A pilot study. Alcohol Alcohol., 2011, <lb/>46(5), 509-513. <lb/>http://dx.doi.org/10.1093/alcalc/agr045 PMID: 21613303 <lb/>[5] <lb/>Crime., U.N.O.o.D.a., World Drug Report 2023; United Nations: <lb/>New York, NY, 2023. <lb/>[6] <lb/>Organization, W.H. WHO global report on trends in prevalence of <lb/>tobacco use 2000-2030; World Health Organization, 2024. <lb/>[7] <lb/>Dai, X.; Gakidou, E.; Lopez, A.D. Evolution of the global smoking <lb/>epidemic over the past half century: Strengthening the evidence <lb/>base for policy action. Tob. Control, 2022, 31(2), 129-137. <lb/>http://dx.doi.org/10.1136/tobaccocontrol-2021-056535 PMID: <lb/>35241576 <lb/>[8] <lb/>WHO Report on GLOBAL TOBACCO Epidemic; 2023; Protect <lb/>people for tobacco smoke. WHO 2023. <lb/>[9] <lb/>Howes, O.D.; Kapur, S. The dopamine hypothesis of schizophre-<lb/>nia: version III-the final common pathway. Schizophr. Bull., 2009, <lb/>35(3), 549-562. <lb/>http://dx.doi.org/10.1093/schbul/sbp006 PMID: 19325164 <lb/>[10] <lb/>Klausen, M.K.; Thomsen, M.; Wortwein, G.; Fink-Jensen, A. The <lb/>role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br. <lb/>J. Pharmacol., 2022, 179(4), 625-641. <lb/>http://dx.doi.org/10.1111/bph.15677 PMID: 34532853 <lb/>[11] <lb/>Zhang, X.; Belousoff , M.J.; Zhao, P.; Kooistra, A.J.; Truong, T.T.; <lb/>Ang, S.Y.; Underwood, C.R.; Egebjerg, T.; Šenel, P.; Stewart, G.D. <lb/>Differential GLP-1R binding and activation by peptide and non-<lb/>peptide agonists. Mol Cell., 2020, 80(3), 485-500. <lb/>[12] <lb/>Volkow, N.D.; Wise, R.A.; Baler, R. The dopamine motive system: <lb/>Implications for drug and food addiction. Nat. Rev. Neurosci., <lb/>2017, 18(12), 741-752. <lb/>http://dx.doi.org/10.1038/nrn.2017.130 PMID: 29142296 <lb/>[13] <lb/>Blum, K.; Kozlowski, G. Ethanol and neuromodulator interactions: <lb/>A cascade model of reward. In: Alcohol and Behavior; VSP Press, <lb/>1990; pp. 131-149. <lb/>[14] <lb/>Rebosio, C.; Balbi, M.; Passalacqua, M.; Ricciarelli, R.; Fedele, E. <lb/>Presynaptic GLP-1 receptors enhance the depolarization-evoked re-<lb/>lease of glutamate and GABA in the mouse cortex and hippocam-<lb/>pus. Biofactors, 2018, 44(2), 148-157. <lb/>http://dx.doi.org/10.1002/biof.1406 PMID: 29265673 <lb/>[15] <lb/>Brodnik, Z.D.; Batra, A.; Oleson, E.B.; España, R.A. Local <lb/>GABAA receptor-mediated suppression of dopamine release within <lb/>the nucleus accumbens. ACS Chem. Neurosci., 2019, 10(4), 1978-<lb/>1985. <lb/>http://dx.doi.org/10.1021/acschemneuro.8b00268 PMID: 30253088 <lb/>[16] <lb/>Chuong, V.; Farokhnia, M.; Khom, S.; Pince, C.L.; Elvig, S.K.; <lb/>Vlkolinsky, R.; Marchette, R.C.N.; Koob, G.F.; Roberto, M.; <lb/>Vendruscolo, L.F.; Leggio, L. The glucagon-like peptide-1 (GLP-1) <lb/>analogue semaglutide reduces alcohol drinking and modulates cen-<lb/>tral GABA neurotransmission. JCI Insight, 2023, 8(12), e170671. <lb/>http://dx.doi.org/10.1172/jci.insight.170671 PMID: 37192005 <lb/>[17] <lb/>Andreadis, P.; Karagiannis, T.; Malandris, K.; Avgerinos, I.; Lia-<lb/>kos, A.; Manolopoulos, A.; Bekiari, E.; Matthews, D.R.; Tsapas, A. <lb/>Semaglutide for type 2 diabetes mellitus: A systematic review and <lb/>meta-analysis. Diabetes Obes. Metab., 2018, 20(9), 2255-2263. <lb/>http://dx.doi.org/10.1111/dom.13361 PMID: 29756388 <lb/>[18] <lb/>Htike, Z.Z.; Zaccardi, F.; Papamargaritis, D.; Webb, D.R.; Khunti, <lb/>K.; Davies, M.J. Efficacy and safety of glucagon-like peptide-1 re-<lb/>ceptor agonists in type 2 diabetes: A systematic review and mixed-<lb/>treatment comparison analysis. Diabetes Obes. Metab., 2017, <lb/>19(4), 524-536. <lb/>http://dx.doi.org/10.1111/dom.12849 PMID: 27981757 <lb/>[19] <lb/>Gerstein, H.C.; Colhoun, H.M.; Dagenais, G.R.; Diaz, R.; Laksh-<lb/>manan, M.; Pais, P.; Probstfield, J.; Riesmeyer, J.S.; Riddle, M.C.; <lb/>Rydén, L.; Xavier, D.; Atisso, C.M.; Dyal, L.; Hall, S.; Rao-<lb/>Melacini, P.; Wong, G.; Avezum, A.; Basile, J.; Chung, N.; Con-<lb/>get, I.; Cushman, W.C.; Franek, E.; Hancu, N.; Hanefeld, M.; Holt, <lb/>S.; Jansky, P.; Keltai, M.; Lanas, F.; Leiter, L.A.; Lopez-Jaramillo, <lb/>P.; Cardona Munoz, E.G.; Pirags, V.; Pogosova, N.; Raubenheimer, <lb/>P.J.; Shaw, J.E.; Sheu, W.H.H.; Temelkova-Kurktschiev, T.; Abel-<lb/>la, M.; Alebuena, A.; Almagro, S.; Amoroso, E.; Anadon, P.; An-<lb/>dreu, E.; Aristimuño, G.; Arzadun, M.; Barbieri, M.; Barcudi, R.; <lb/>Bartolacci, I.; Bolobanich, G.; Bordonava, A.; Bustamante Labarta, <lb/>M.; Bustos, B.; Caccavo, A.; Camino, A.; Cantero, M.; Carignano, <lb/>M.; Cartasegna, L.; Cipullo, M.; Commendatore, V.; Conosciuto, <lb/>V.; Costamagna, O.; Crespo, C.; Cuello, J.; Cuneo, C.; Cusimano, <lb/>S.; Dean, S.; Dituro, C.; Dominguez, A.; Farah, M.; Fernandez, A.; <lb/>Fernandez, F.; Ferrari, A.; Flammia, P.; Fuentealba, J.; Gallardo, <lb/>K.B.; Garcia, C.; Garcia, D.R.; Garrido, M.; Gavicola, R.; Gerbau-<lb/>do, C.; Gilli, G.; Giotto, A.P.; Godoy Bolzán, P.; Gomez Vilamajo, <lb/>O.; Guerlloy, F.; Guridi, C.; Gutierrez Garrido, N.; Hasbani, E.; <lb/>Hermida, S.; Hominal, M.; Hrabar, A.; Ingaramo, A.; Izzicupo, A.; <lb/>Krynski, M.; Lagrutta, M.; Lanchiotti, P.; Langhe, M.; Leonard, V.; <lb/>Llanos, J.; Lopez Santi, R.; Lowenstein, J.; Luquez, C.; Mackin-<lb/>non, I.; Mana, M.; Manzur, S.; Marino, J.; Martella, C.; Martinez, <lb/>R.; Matias, R.; Matkovich, J.; Meritano, M.; Montaña, O.; Mulazzi, <lb/>M.; Ochoa, J.; Paterlini, G.; Pelagagge, M.; Peralta Lopez, M.E.; <lb/>Prado, A.; Pruyas, L.; Racca, M.; Ricotti, C.; Rodriguez, C.; <lb/>Romero Vidomlansky, M.; Ronderos, R.; Sadowski, A.L.; Sala, J.; <lb/>Sánchez, A.; Santoro, A.; Schiavi, L.; Sein, M.; Sernia, V.; Serra, <lb/>L.; Sicer, M.; Smith, T.; Soso, L.; Sposetti, G.; Steinacher, A.; Sti-<lb/>val, J.; Tedesco, J.; Tonin, H.; Tortolo, M.; Ulla, M.; Vallejos, J.; <lb/>Vico, M.; Virgillito, L.; Visco, V.; Vogel, D.; Waisman, F.; Zaid-<lb/>man, C.; Zucchiatti, N.; Badshah, I.; Cohen, N.; Colman, P.; <lb/>Colquhoun, D.; Davis, T.; Fourlanos, S.; Fulcher, G.; Hamlyn, J.; <lb/>Haywood, C.; Hocking, S.; Huchinson, M.; Jeffries, W.; Kyl, M.; <lb/>Lo, C.; Mah, P.M.; Makepeace, A.; Marope, D.; Nanayakkar, N.; <lb/>Nankervis, A.; Palmer, N.; Palolus, B.; Pillai, S.; Price, S.; Price, <lb/>S.; Proietto, J.; Reutens, A.; Rodrigo, N.; Sheikh, A.; Smith, G.; So, <lb/>M.; Soldatos, G.; Stuckey, B.; Sumithran, P.; Teede, H.; Vora, P.; <lb/>Williams, L.; Abib, E.; Adão Poço, C.; Alves, É.F.; Andreatta Ber-<lb/>nardi Barea, J.; Avezum Oliveira, L.; Castro, D.L.C.; Correa da <lb/>Cruz, I.; Costa, M.; Cruz, I.; Cunha, S.; Da Silva, M.A.V.; de Car-<lb/>valho Camara Bona, R.; de Paula, B.; Eliaschewitz, F.; Fazolli, G.; <lb/>Ferreira Filho, C.A.; Fortes, J.; França, C.; Franco, D.R.; <lb/>Genestreti, P.R.; Giorgeto, F.; Gonçalves, R.M.; Grossman, M.E.; <lb/>PGx of GLP1 Agonists and GARS <lb/></listBibl>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
			
			<page>991 <lb/></page>
			
			<listBibl>Henrique Marcelino, A.C.; Hernandes, M.; Horta, A.; Jaeger, C.; <lb/>Kaneblai, M.; Kauffman Rutenberg, C.; Kerr Saraiva, J.F.; Lemos, <lb/>M.A.; Maia, L.; Manenti, E.R.; Marques, M.; Melissa Valerio, C.; <lb/>Moreira, R.; Mothé, F.; Mouco, O.M.; Moura, P.; Moura Jorge, <lb/>J.C.; Nakashima, C.; Nakazone, M.; Napoli, T.; Nunes, C.; Nunes <lb/>Salles, J.E.; Oliveira, K.; Oliveira, M.; Pantano, G.S.; Petri, F.; Pi-<lb/>azza, L.; Pires, A.C.; Pizzato, P.; Prata, S.; Precoma, D.; Rech, R.; <lb/>Reis, G.; Reis, H.; Resende, E.; Ribas Fortes, J.; Rodovalho, S.; <lb/>Rossi dos Santos, F.; Salles, J.E.; Sampaio, C.R.; Santos, T.; Santos <lb/>dos Santos, V.; Silva e Quadros, T.; Silveira, D.; Siqueira, K.N.; <lb/>Teireira, M.; Uehara, M.; Valerio, C.; Vianna, H.; Vidotti, M.H.; <lb/>Visconti, G.L.; Zanella, M.T.; Andreeva, V.; Borisov, R.; Bot-<lb/>ushanov, N.; Dimitrov, G.; Dimova, K.; Dragoychev, T.; Grigo-<lb/>rova, V.; Gushterova, V.; Ivanov, I.; Kocelova, T.; Kurktschiev, D.; <lb/>Miletieva, M.; Nenkova-Gugusheva, N.; Pancheva, R.; Pavlova, <lb/>M.; Raev, D.; Spasova, V.; Stoikov, A.; Troev, D.; Yanev, T.; <lb/>Yoncheva-Mihaylova, M.; Abitbol, A.; Ajala, B.; Alguwaihes, A.; <lb/>Ardilouze, J-L.; Aris-Jilwan, N.; Arnaout, A.; Aronson, R.; Aslam, <lb/>N.; Babin, S.; Bailargeon, J-P.; Bailey, A.; Bajaj, H.; Beauchesne, <lb/>C.; Beca, S.; Belanger, A.; Bell, A.; Bellabarba, D.; Berard, L.; <lb/>Berenbaum, B.; Bergeron, V.; Berlingieri, J.; Bernier, F.; Bishara, <lb/>P.; Blank, D.; Blumer, I.; Brault, S.; Breton, D.; Carpentier, A.; <lb/>Cha, J.; Chandra, P.; Chiasson, J-L.; Conway, J.R.; Couture, G.; <lb/>Couture, N.; Dagenais, G.; Datta, D.; D&apos;Ignazio, G.; Dumas, R.; <lb/>Fay, D.; Frechette, A.; Frenette, L.; Fung, D.; Gagnon, N.; Galter, <lb/>M.; Garon, J.; Gauthier, J.S.; Geadah, C.; Gilbert, J.; Girard, R.; <lb/>Goldenberg, R.; Grossman, L.D.; Gupta, N.; Halle, J-P.; Hivert, M-<lb/>F.; Houde, G.; Houlden, R.; Hramiak, I.; Jablonski, T.; Jain, A.J.; <lb/>Khandwala, H.; Khosla, M.; Lachance, C.; Laflamme, E.; Langlois, <lb/>M-F.; Larivee, L.; Liutkus, J.; Lochnan, H.; Malik, S.; McDonald, <lb/>C.; Mehta, P.; Mihailidis, J.; Milot, A.; Narula, P.; Nault, P.; Nayar, <lb/>A.; Nisker, W.; Ouellet, G.; Palardy, J.; Patel, M.; Paul, T.; Peder-<lb/>sen, S.; Perron, P.; Pesant, M-H.; Poirier, P.; Poulin, M-C.; Puntha-<lb/>kee, Z.; Rehman, W.; Ross, S.; Sagar, P.; Saliba, N.; Sandler, S.; <lb/>Schiffrin, A.; Schlosser, R.; Seth-Sharma, A.; Sherman, M.; Sionit, <lb/>D.; Sivakumar, T.; Soto, J.; St-Amour, E.; Steen, O.; Sussman, J.; <lb/>Telner, A.; Tobe, S.; Twum-Barima, D-Y.; Van Zanten, A.; <lb/>VanRossum, N.; Vecchiarelli, J.; Ward, R.; Wessengel, J.; Weisna-<lb/>gel, S.; Wilderman, I.; Woo, V.; Yakubovich, N.; Yale, J-F.; Yared, <lb/>Z.; Acevedo, M.; Aguirre, M.L.; Aizman, A.; Barroso, M.S.; Co-<lb/>bos, L.; Danin Vargas, A.; Descalzi, B.; Godoy, G.; Grumberg, E.; <lb/>Lahsen, R.; Larenas, G.; Ortiz, E.; Paredes, J.; Potthoff, S.; Reta-<lb/>mal, E.; Rojas, L.; Salgado, M.; Santibanez, C.; Solis, C.; Stokins, <lb/>B.; Accini, J.; Acebedo, J.; Agudelo Baena, L.M.; Alarcon, S.; An-<lb/>gel, J.; Arcos, E.; Aroca Martinez, M.; Atuesta, L.; Balaguera, J.; <lb/>Ballestas, D.; Barrera, S.I.; Barrios Reyes, R.; Bayona, A.; Bermu-<lb/>dez, A.; Bernal, D.Z.; Blanquicett, M.; Bravo, V.; Bueno, W.; Bur-<lb/>bano Delgado, A.; Cadena, A.; Cadena, A.; Caicedo, S.; Celemin, <lb/>C.; Consuegra, R.; Contreras Pimienta, C.; Corredor, K.J.; Cure, <lb/>C.; De La Hoz Rueda, L.D.; Delgado, E.; Diaz, S.; Diego, M.; Do-<lb/>nado, A.; Encinales Sanabria, W.; Escobar, J.; Escorcia, G.; Forero, <lb/>L.; Fuentes, L.; Garcia, M.; Garcia Lozada, H.; Garcia Ortiz, L.; <lb/>Giraldo, A.; Gomez Gonzalez, L.; Granada, J.; Gutierrez, C.; He-<lb/>nao, N.; Hernandez, E.; Herrera Uejbe, O.M.; Higuera Cobos, J.D.; <lb/>Ibarra Gómez, J.; Jaimes, E.H.; Jaramillo, M.; Jaramillo, N.; Jara-<lb/>millo Gomez, C.; Jaramillo Sanchez, M.; Jarava Durán, I.; Lopez <lb/>Ceballos, C.; Madrid, C.; María Amastha, E.; Mercado, J.; Molina, <lb/>D.I.; Molina Soto, J.; Montoya, C.; Morales, A.; Muñoz, C.; Oroz-<lb/>co, L.A.; Osorio, O.; Palmera Sanchez, J.M.; Peña, A.; Perez, J.; <lb/>Perez Agudelo, J.; Pérez Amador, G.; Pertuz, C.; Posada, I.; Puerta, <lb/>C.; Quintero, A.; Quiroz, D.; Rendon, C.; Reyes, A.; Reyes, A.; <lb/>Ripoll, D.; Rivera, C.; Rocha, M.; Rodriguez, J.F.; Rodriguez Vil-<lb/>lanueva, K.A.; Rodriguez Zabala, J.E.; Rojas, S.; Romero, M.; Ro-<lb/>sero, R.; Rosillo Cardenas, A.R.; Rueda, L.; Sanchez, G.; Sanchez, <lb/>T.; Sotomayor Herazo, A.; Suarez, M.; Torres, M.; Trujillo, F.; <lb/>Urina, M.; Van Strahlen, L.; Velandia, C.; Velasquez Guzman, C.; <lb/>Velazquez, E.; Vidal Prada, T.; Yepez Alvaran, J.P.; Zarate, D.; <lb/>Andelova, J.; Benesova, R.; Buzova, B.; Cech, V.; Chodova, I.; <lb/>Choura, M.; Dufka, A.; Gamova, A.; Gorgol, J.; Hala, T.; Havlova, <lb/>H.; Hlavkova, D.; Horanska, P.; Ilcisin-Valova, J.; Jenickova, P.; <lb/>Jerabek, O.; Kantorova, I.; Kolomaznikova, K.; Kopeckova, I.; Ko-<lb/>peckova, M.; Linhart, K.; Linhart, T.; Malecha, J.; Malicherova, E.; <lb/>Neubauerova, D.; Oznerova, M.; Partys, R.; Pederzoliova, E.; <lb/>Petrusova, M.; Prymkova, V.; Racicka, E.; Reissova, I.; Roderova, <lb/>E.; Stanek, L.; Striova, A.; Svarcova, D.; Svoboda, P.; Szeghy Ma-<lb/>licharova, E.; Urge, J.; Vesely, L.; Wasserburger, B.; Wasser-<lb/>burgerova, H.; Zahumensky, E.; Zamrazil, V.; Alawi, H.; Anastasi-<lb/>adis, E.; Axthelm, E.; Bieler, T.; Buhrig, C.; Degtyareva, E.; Del-<lb/>lanna, F.; Derwahl, K-M.; Diessel, S.; Dogiami, B.; Dorn-Weitzel, <lb/>K.; Ernst, M.; Faulmann, G.; Fetscher, B.; Forst, T.; Freyer-Lahres, <lb/>G.; Funke, K.; Ganz, X.; Gleixner, C.; Hanefeld, C.; Heinrichs, S.; <lb/>Helleberg, S.; Henkel, E.; Hetzel, G.R.; Hoffmann, C.; Jacob, F.; <lb/>Jacob, S.; John, F.; Jonczyk, A.; Kamke, W.; Klein, C.; Kleinhardt, <lb/>M.; Kleophas, W.; Kosch, C.; Kreutzmann, K.; Kühn, A.; Lee-<lb/>Barkey, Y.H.; Lier, A.; Maatouk, S.; Minnich, J.; Mitry, M.; <lb/>Muessig, I.; Nicula, D.; Niemann, M.; Nothroff, J.; Ott, P.; <lb/>Pfuetzner, A.; Pfützner, A.; Pistrosch, F.; Pohl, W.; Prochazkova, <lb/>Z.; Retkowska, M.; Rosin, H.; Sachsenheimer, D.; Samer, H.; <lb/>Sanuri, M.; Schaefer, A.; Schaper, F.; Schulze, E-D.; Schulze, M.; <lb/>Schumann, M.; Segiet, T.; Sowa, V.; Stahl, H-D.; Steinfeldt, F.; <lb/>Teige, M.; Trieb, B.; Tschoepe, D.; Uebel, P.; Warken, B.; Weig-<lb/>mann, I.; Weyland, K.; Wilhelm, K.; Balo, T.; Balsay, M.; Bende, <lb/>I.; Bezzegh, K.; Birkus, Z.; Buday, B.; Csomai, M.; Deak, L.; <lb/>Dezso, E.; Faludi, P.; Faluvegi, M.; Fazekas, I.; Feher, A.; Fejer, <lb/>C.; Finta, E.; Fulcz, A.; Gaal, Z.; Gurzo, M.; Hati, K.; Herczeg, G.; <lb/>Jozsef, I.; Juhasz, M.; Keltai, K.; Koranyi, L.; Kulcsar, E.; Kun, K.; <lb/>Laczko, A.; Literáti-Nagy, B.; Mezo, I.; Mileder, M.; Moricz, I.; <lb/>Nagy, K.; Nagybaczoni, B.; Nemeth, C.; Oze, A.; Pauer, J.; Peter-<lb/>fai, E.; Polocsanyi, B.; Poor, F.; Reiber, I.; Salamon, C.; Sebestyen, <lb/>J.; Torok, I.; Tuu, M.; Varga, A.; Vass, V.; Ahn, C.M.; Ahn, C.; <lb/>ByungWon, P.; Chang, H-J.; Chang, K.; Choi, E-Y.; Choi, H.S.; <lb/>Chung, J-W.; Hong, B-K.; Hong, Y.J.; Hyon, M.S.; Jeong, M.H.; <lb/>Kang, S.; Kim, B-K.; Kim, J-H.; Kim, J.H.; Kim, K-S.; Kim, K-S.; <lb/>Kim, M.H.; Kim, P-J.; Kim, S-K.; Kim, Y-S.; Kim, Y.K.; Koh, <lb/>Y.S.; Kwon, H.M.; Lee, B.K.; Lee, B-W.; Lee, J.B.; Lee, M-M.; <lb/>Lim, Y-M.; Min, P.K.; Park, J.S.; Park, J.; Park, K.H.; Park, S.; <lb/>Pyun, W.B.; Rim, S.J.; Ryu, D-R.; Seo, H-S.; Seung, K.B.; Shin, <lb/>D-H.; Sim, D.S.; Yoon, Y.W.; Andersone, I.; Babicka, K.; Balcere, <lb/>I.; Barons, R.; Capkovska, I.; Geldnere, K.; Grigane, I.; Jegere, B.; <lb/>Lagzdina, I.; Mora, L.; Pastare, S.; Ritenberga, R.; Romanova, J.; <lb/>Saknite, I.; Sidlovska, N.; Sokolova, J.; Steina, S.; Strizko, I.; <lb/>Teterovska, D.; Vizina, B.; Barsiene, L.; Belozariene, G.; <lb/>Daugintyte-Petrusiene, L.; Drungiliene, N.; Garsviene, N.; Gri-<lb/>giene, A.; Grizas, V.; Jociene, V.; Kalvaitiene, D.; Kaupiene, J.; <lb/>Kavaliauskiene, J.; Kozloviene, D.; Lapteva, I.; Maneikiene, B.; <lb/>Marcinkeviciene, J.; Markauskiene, V.; Meiluniene, S.; Norkus, A.; <lb/>Norviliene, R.; Petrenko, V.; Radzeviciene, R.; Sakalyte, G.; Ur-<lb/>bonas, G.; Urbutiene, S.; Vasiliauskas, D.; Velickiene, D.; Aguilar, <lb/>C.; Alcocer, M.; Avalos-Ramirez, J.A.; Banda-Elizondo, R.; Bri-<lb/>cio-Ramirez, R.; Cardenas, M.K.; Cavazos, F.; Chapa, J.; Cienfue-<lb/>gos, E.; De la Peña, A.; de la Peña Topete, G.; De los Rios Ibarra, <lb/>M.O.; Elias, D.; Flores-Moreno, C.; Garcia, H.P.; Gonzalez, L.G.; <lb/>Guerra Moya, R.L.; Guerra-Lopez, A.; Hernandez, B.R.; Herrera, <lb/>C.C.; Herrera-Marmolejo, M.; Islas-Palacios, N.; Lopez, E.; Lopez, <lb/>F.; Lopez, A.A.; Luna, C.R.I.; Morales, V.E.; Moreno-Virgen, G.; <lb/>Parra Perez, R.L.; Pascoe, G.S.; Peralta-Cantu, I.; Previn, R.; <lb/>Ramirez, R.; Ramirez, R.; Ramos, Z.M.G.; Rodriguez, M.; Salga-<lb/>do-Sedano, R.; Sanchez-Aguilar, A.C.; Santa Rosa Franco, E.; <lb/>Sauque-Reyna, L.; Suarez Otero, R.; Torres, I.; Velarde-<lb/>Harnandez, E.; Villagordoa, J.; Villeda-Espinoza, E.; Vital-Lopez, <lb/>J.; Zavala-Bello, C.J.; Baker, J.; Barrington-Ward, E.; Brownless, <lb/>T.; Carroll, R.; Carson, S.; Choe, M.; Corin, A.; Corley, B.; Cut-<lb/>field, R.; Dalaman, N.; Dixon, P.; Drury, P.; Dyson, K.; Florkow-<lb/>ski, C.; Ford, M.; Frengley, W.; Helm, C.; Katzen, C.; Kerr, J.; <lb/>Khanolkar, M.; Kim, D.; Koops, R.; Krebs, J.; Leikis, R.; Low, K.; <lb/>Luckey, A.; Luke, R.; Macaulay, S.; Marks, R.; McNamara, C.; <lb/>Millar-Coote, D.; Miller, S.; Mottershead, N.; Reid, J.; Robertson, <lb/>N.; Rosen, I.; Rowe, D.; Schmiedel, O.; Scott, R.; Sebastian, J.; <lb/>Sheahan, D.; Stiebel, V.; Ternouth, I.; Tofield, C.; Venter, D.; Wil-<lb/>liams, M.; Williams, M.; Wu, F.; Young, S.; Arciszewska, M.; <lb/>Bochenek, A.; Borkowski, P.; Borowy, P.; Chrzanowski, T.; Czer-<lb/>winski, E.; Dwojak, M.; Grodzicka, A.; Janiec, I.; Jaruga, J.; <lb/>Jazwinska-Tarnawska, E.K.; Jedynasty, K.; Juzwiak-Czapiewska, <lb/>D.; Karczewicz-Janowska, J.; Konieczny, J.; Konieczny, M.; <lb/>Korol, M.; Kozina, M.; Krzyzagorska, E.; Kucharczyk-Petryka, E.; <lb/>Laz, R.; Majchrzak, A.; Mrozowska, Z.; Mularczyk, M.; Nowacka, <lb/>E.; Peczynska, J.; Petryka, R.; Pietrzak, R.; Pisarczyk-Wiza, D.; <lb/>Rozanska, A.; Ruzga, Z.; Rzeszotarska, E.; Sacha, M.; Sekulska, <lb/></listBibl>

			<page>992 </page>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/> Sharafshah et al. <lb/></note>

			<listBibl>M.; Sidorowicz-Bialynicka, A.; Stasinska, T.; Strzelecka-Sosik, A.; <lb/>Swierszcz, T.; Szymkowiak, K.M.; Turowska, O.; Wisniewska, K.; <lb/>Wiza, M.; Wozniak, I.; Zelazowska, K.; Ziolkowska-Gawron, B.; <lb/>Zytkiewicz-Jaruga, D.; Albota, A.; Alexandru, C.; Avram, R.; Bala, <lb/>C.; Barbonta, D.; Barbu, R.; Braicu, D.; Calutiu, N.; Catrinoiu, D.; <lb/>Cerghizan, A.; Ciorba, A.; Craciun, A.; Doros, R.; Duma, L.; Du-<lb/>mitrache, A.; Ferariu, I.; Ferician Moza, A.; Ghergan, A.; Ghise, <lb/>G.; Graur, M.; Gribovschi, M.; Mihai, B.; Mihalache, L.; Mihalcea, <lb/>M.; Mindrescu, N.; Morosanu, M.; Morosoanu, A.; Mota, M.; Mo-<lb/>za, A.; Nafornita, V.; Natea, N.; Nicodim, S.; Nita, C.; Onaca, A.; <lb/>Onaca, M.; Pop, C.; Pop, L.; Popa, A.; Popescu, A.; Pruna, L.; Ro-<lb/>man, G.; Rosu, M.; Sima, A.; Sipciu, D.; Sitterli-Natea, C.N.; Szil-<lb/>agyi, I.; Tapurica, M.; Tase, A.; Tutescu, A-C.; Vanghelie, L.; <lb/>Verde, I.; Vlad, A.; Zarnescu, M.; Akhmetov, R.; Allenova, I.; Av-<lb/>deeva, I.; Baturina, O.; Biserova, I.; Bokovin, N.; Bondar, I.; Bu-<lb/>rova, N.; Chufeneva, G.; Chumachek, E.; Demidova, M.; Demin, <lb/>A.; Drobysheva, V.; Egorova, I.; Esenyan, L.; Gelig, E.; Gilyarev-<lb/>sky, S.; Golshmid, M.; Goncharov, A.; Gorbunova, A.; Gordeev, I.; <lb/>Gorelysheva, V.; Goryunova, T.; Grebenshchikova, I.; Ilchenko, <lb/>R.; Ivannikova, M.; Karabalieva, S.; Karpeeva, J.; Khaykina, E.; <lb/>Kobalava, Z.; Kononenko, I.; Korolik, O.; Korshunova, A.; <lb/>Kostenko, V.; Krasnopevtseva, I.; Krylova, L.; Kulkova, P.; <lb/>Kuzmina, I.; Ledyaeva, A.; Levashov, S.; Lokhovinina, N.; Lvov, <lb/>V.; Martirosyan, N.; Nedogoda, S.; Nilk, R.; Osmolovskaya, Y.; <lb/>Panov, A.; Paramonova, O.; Pavlova, E.; Pekareva, E.; Petunina, <lb/>N.; Ponamareva, S.; Reshedko, G.; Salasyuk, A.; Sepkhanyan, M.; <lb/>Serebrov, A.; Shabelnikova, O.; Skvortsov, A.; Smirnova, O.; Spir-<lb/>idonova, O.; Strogova, S.; Taratukhin, E.; Tereschenko, S.; <lb/>Trukhina, L.; Tsarkova, O.; Tsoma, V.; Tumarov, F.; Tyan, N.; <lb/>Tyurina, T.; Villevalde, S.; Yankovaya, E.; Zarutskaya, L.; Zenko-<lb/>va, E.; Badat, A.; Bester, F.; Blignaut, S.; Blom, D.; Booysen, S.; <lb/>Boyd, W.; Brice, B.; Brown, S.; Burgess, L.; Cawood, R.; Coetzee, <lb/>K.; Conradie, H.; Cronje, T.; de Jong, D.; Ellis, G.; Emanuel, S.; <lb/>Engelbrecht, I.; Foulkes, S.; Fourie, D.; Gibson, G.; Govender, T.; <lb/>Hansa, S.; Hemus, A.C.; Hendricks, F.; Heradien, M.; Holmgren, <lb/>C.; Hoosain, Z.; Horak, E.; Howard, J.; Immink, I.; Janari, E.; <lb/>Jivan, D.; Klusmann, K.; Labuschagne, W.; Lai, Y.; Latiff, G.; <lb/>Lombaard, J.; Lottering, H.; Meeding, R.; Middlemost, S.; Mitha, <lb/>H.; Mitha, I.; Mkhwanazi, S.; Moodley, R.; Murray, A.; <lb/>Musungaie, D.; Osman, Y.; Peacey, K.; Pillay-Ramaya, L.; Pretori-<lb/>us, C.; Prozesky, H.; Sarvan, M.; Scholtz, E.; Sebesteny, A.; Skin-<lb/>ner, B.; Skriker, M.; Smit, M.; Stapelberg, A-M.; Swanepoel, N.; <lb/>Urbach, D.; van Aswegen, D.; van Zyl, F.; Van Zyl, L.; Venter, E.; <lb/>Wadvalla, S.; Wing, J.; Wolmarans, K.; Abreu, C.; Aguilà, P.; <lb/>Aguilera, E.; Alonso, N.; Alvarez, C.; Cajas, P.; Castro, J.C.; <lb/>Codinachs, R.; Contreras, J.; Coves, M.J.; Fajardo, C.; Ferrer, J.C.; <lb/>Font, N.; Garcia, M.; Gil, M.A.; Gomez, F.; Gomez, L.A.; Gonzal-<lb/>bez, J.; Griera, J.L.; Masmiquel, L.; Mauricio, D.; Narejos Perez, <lb/>S.; Nicolau, J.A.; Noheda Contreras, O.; Olivan, J.; Olivares, J.; <lb/>Ortega, E.; Pellitero, S.; Pertusa, S.; Rius, F.; Rodriguez, I.; <lb/>Sánchez-Juan, C.; Santos, D.; Soldevila, B.; Subias, D.; Terns, M.; <lb/>Trescoli, C.; Vilaplana, J.; Villanueva, A.; Albo, J.; Antus, K.; Ax-<lb/>elsson, M.; Bergström, L.; Binsell-Gerdin, E.; Boman, K.; Botond, <lb/>F.; Dotevall, A.; Graipe, A.; Jarnet, C.; Kaminska, J.; Kempe, A.; <lb/>Korhonen, M.; Linderfalk, C.; Liu, B.; Ljungstroem, K.; Ljung-<lb/>ström, K.; Malmqvist, L.; Mellbin, L.; Mooe, T.; Nicol, P.; Norrby, <lb/>A.; Ohlsson, A.; Rosengren, A.; Saaf, J.; Salmonsson, S.; Strand-<lb/>berg, O.; Svensson, K-A.; Tengmark, B-O.; Tsatsaris, G.; Ulven-<lb/>stam, A.; Vasko, P.; Chang, C-T.; Chang, H-M.; Chen, J-F.; Chen, <lb/>T-P.; Chung, M-M.; Fu, C-P.; Hsia, T-L.; Hua, S-C.; Kuo, M-C.; <lb/>Lee, C.; Lee, I-T.; Liang, K-W.; Lin, S.Y.; Lu, C-H.; Ma, W-Y.; <lb/>Pei, D.; Shen, F-C.; Su, C-C.; Su, S-W.; Tai, T-S.; Tsai, W-N.; <lb/>Tsai, Y-T.; Tung, S-C.; Wang, J-S.; Yu, H-I.; Al-Qaissi, A.; <lb/>Arutchelvam, V.; Atkin, S.; Au, S.; Aye, M.M.; Bain, S.; Bejnariu, <lb/>C.; Bell, P.; Bhatnagar, D.; Bilous, R.; Black, N.; Brennan, U.; <lb/>Brett, B.; Bujanova, J.; Chow, E.; Collier, A.; Combe, A.; Court-<lb/>ney, C.; Courtney, H.; Crothers, J.; Eavis, P.; Elliott, J.; Febbraro, <lb/>S.; Finlayson, J.; Gandhi, R.; Gillings, S.; Hamling, J.; Harper, R.; <lb/>Harris, T.; Hassan, K.; Heller, S.; Jane, A.; Javed, Z.; Johnson, T.; <lb/>Jones, S.; Kennedy, A.; Kerr, D.; Kilgallon, B.; Konya, J.; Lindsay, <lb/>J.; Lomova-Williams, L.; Looker, H.; MacFarlane, D.; Macrury, S.; <lb/>Malik, I.; McCrimmon, R.; McKeith, D.; McKnight, J.; Mishra, B.; <lb/>Mukhtar, R.; Mulligan, C.; O&apos;Kane, M.; Olateju, T.; Orpen, I.; <lb/>Richardson, T.; Rooney, D.; Ross, S.B.; Sathyapalan, T.; Siddara-<lb/>maiah, N.; Sit, L.E.; Stephens, J.; Turtle, F.; Wakil, A.; <lb/>Walkinshaw, E.; Ali, A.; Anderson, R.; Arakaki, R.; Aref, O.; Ari-<lb/>ani, M.K.; Arkin, D.; Banarer, S.; Barchini, G.; Bhan, A.; Branch, <lb/>K.; Brautigam, D.; Brietzke, S.; Brinas, M.; Brito, Y.; Carter, C.; <lb/>Casagni, K.; Casula, S.; Chakko, S.; Charatz, S.; Childress, D.; <lb/>Chow, L.; Chustecka, M.; Clarke, S.; Cohen, L.; Collins, B.; Colon <lb/>Vega, G.; Comulada-Rivera, A.; Cortes-Maisonet, G.; Davis, M.; <lb/>de Souza, J.; Desouza, C.; Dinnan, M.; Duffy-Hidalgo, B.; Dunn, <lb/>B.; Dunn, J.; Elman, M.; Felicetta, J.; Finkelstein, S.; Fitz-Patrick, <lb/>D.; Florez, H.; Forker, A.; Fowler, W.; Fredrickson, S.; Freedman, <lb/>Z.; Gainey Narron, B.; Gainey-Ferree, K.; Gardner, M.; Gastelum, <lb/>C.; Giddings, S.; Gillespie, E.; Gimness, M.P.; Goldstein, G.; <lb/>Gomes, M.; Gomez, N.; Gorman, T.; Goswami, K.; Graves, A.; <lb/>Hacking, S.; Hall, C.; Hanson, L.; Harman, S.; Heber, D.; Henry, <lb/>R.; Hiner, J.; Hirsch, I.; Hollander, P.; Hooker, T.; Horowitz, B.; <lb/>Hoste, L.; Huang, L.; Huynh, M.; Hyman, D.; Idriss, S.; Iran-<lb/>manesh, A.; Karounos, D.; Kashyap, M.; Katz, L.; Kaye, W.; Khai-<lb/>ton, Y.; Khardori, R.; Kitchen, T.; Klein, A.; Knffem, W.; Kosibo-<lb/>rod, M.; Kreglinger, N.; Kruger, D.; Kumar, A.; Laboy, I.; Larra-<lb/>bee, P.; Larrick, L.; Lawson, D.; Ledet, M.; Lenhard, J.; Levy, J.; <lb/>Li, G.; Li, Z.; Lieb, D.; Limcolioc, A.; Lions-Patterson, J.; Lorber, <lb/>D.; Lorch, D.; Lorrello, M.; Lu, P.; Lucas, K.J.; Ma, S-L.; MacAd-<lb/>ams, M.; Magee, M.; Magno, A.; Mahakala, A.R.; Marks, J.; <lb/>McCall, A.; McClanahan, W., Jr; McClary, C.; Melendez, L.; <lb/>Melish, J.; Michaud, D.; Miller, C.; Miller, N.; Mora, P.; Moten, <lb/>M.; Mudaliar, S.; Myrick, G.; Narayan, P.; Nassif, M.; Neri, K.; <lb/>Newton, T.; Niblack, P.; Nicol, P.; Nyenwe, E.; Odugbesan, A.O.; <lb/>Okorocha, Y.; Ortiz, C.R.; Osei, K.; Palermo, C.; Patel, H.; Patel, <lb/>K.; Pau, C.; Perley, M.; Plevin, S.; Plummer, E.; Powell, R.; Qintar, <lb/>M.; Rawls, R.; Reyes-Castano, J.; Reynolds, L.; Richards, R.; <lb/>Rosenstock, J.; Rowe, C.; Saleh, J.; Sam, S.; Sanchez, A.; Sander, <lb/>D.; Sanderson, B.; Savin, V.; Seaquist, E.; Shah, J.; Shi, S.; Shi-<lb/>vaswamy, V.; Shlotzhauer, T.; Shore, D.; Skukowski, B.; Soe, K.; <lb/>Solheim, V.; Soufer, J.; Steinberg, H.; Steinsapir, J.; Tarkington, <lb/>P.; Thayer, D.; Thomson, S.; Thrasher, J.; Tibaldi, J.; Tjaden, J.; <lb/>Tores, O.; Trence, D.; Trikudanathan, S.; Ullal, J.; Uwaifo, G.; Vo, <lb/>A.; Vu, K.; Walia, D.; Weiland, K.; Whitehouse, F.; Wiegmann, T.; <lb/>Wyne, K.; Wynne, A.; Yuen, K.; Zaretzky, J.; Zebrack, J.; Zieve, <lb/>F.; Zigrang, W. Dulaglutide and cardiovascular outcomes in type 2 <lb/>diabetes (REWIND): A double-blind, randomised placebo-<lb/>controlled trial. Lancet, 2019, 394(10193), 121-130. <lb/>http://dx.doi.org/10.1016/S0140-6736(19)31149-3 PMID: <lb/>31189511 <lb/>[20] <lb/>Marso, S.P.; Bain, S.C.; Consoli, A.; Eliaschewitz, F.G.; Jódar, E.; <lb/>Leiter, L.A.; Lingvay, I.; Rosenstock, J.; Seufert, J.; Warren, M.L.; <lb/>Woo, V.; Hansen, O.; Holst, A.G.; Pettersson, J.; Vilsbøll, T. <lb/>Semaglutide and cardiovascular outcomes in patients with type 2 <lb/>diabetes. N. Engl. J. Med., 2016, 375(19), 1834-1844. <lb/>http://dx.doi.org/10.1056/NEJMoa1607141 PMID: 27633186 <lb/>[21] <lb/>Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; <lb/>Mann, J.F.E.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; <lb/>Ravn, L.S.; Steinberg, W.M.; Stockner, M.; Zinman, B.; Bergen-<lb/>stal, R.M.; Buse, J.B. Liraglutide and cardiovascular outcomes in <lb/>type 2 diabetes. N. Engl. J. Med., 2016, 375(4), 311-322. <lb/>http://dx.doi.org/10.1056/NEJMoa1603827 PMID: 27295427 <lb/>[22] <lb/>Takaoka, Y.; Mizuno, A.; Kanie, T.; Yoneoka, D.; Suzuki, T.; <lb/>Nishikawa, Y.; Tam, W.W.S..; Morze, J.; Rynkiewicz, A.; Xin, Y.; <lb/>Wu, O. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 <lb/>receptor agonists and sodium-glucose co-transporter-2 inhibitors <lb/>for people with cardiovascular disease: A network meta-analysis. <lb/>Cochrane Database Syst Rev., 2021, 10(10), CD013650. <lb/>http://dx.doi.org/10.1002/14651858 <lb/>[23] <lb/>Raad, M.; López, W.O.C.; Sharafshah, A.; Assefi, M.; Lewand-<lb/>rowski, K.U. Personalized medicine in cancer pain management. J. <lb/>Pers. Med., 2023, 13(8), 1201. <lb/>http://dx.doi.org/10.3390/jpm13081201 PMID: 37623452 <lb/>[24] <lb/>Suchankova, P.; Yan, J.; Schwandt, M.L.; Stangl, B.L.; Caparelli, <lb/>E.C.; Momenan, R.; Jerlhag, E.; Engel, J.A.; Hodgkinson, C.A.; <lb/>Egli, M.; Lopez, M.F.; Becker, H.C.; Goldman, D.; Heilig, M.; <lb/>Ramchandani, V.A.; Leggio, L. The glucagon-like peptide-1 recep-<lb/>tor as a potential treatment target in alcohol use disorder: Evidence <lb/>from human genetic association studies and a mouse model of al-<lb/>cohol dependence. Transl. Psychiatry, 2015, 5(6), e583-e583. <lb/>http://dx.doi.org/10.1038/tp.2015.68 PMID: 26080318 <lb/></listBibl>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>993 <lb/></page>

			<listBibl>[25] <lb/>Sabaie, H.; Khorami Rouz, S.; Kouchakali, G.; Heydarzadeh, S.; <lb/>Asadi, M.R.; Sharifi-Bonab, M.; Hussen, B.M.; Taheri, M.; Ayatol-<lb/>lahi, S.A.; Rezazadeh, M. Identification of potential regulatory long <lb/>non-coding RNA-associated competing endogenous RNA axes in <lb/>periplaque regions in multiple sclerosis. Front. Genet., 2022, 13, <lb/>1011350. <lb/>http://dx.doi.org/10.3389/fgene.2022.1011350 PMID: 36324503 <lb/>[26] <lb/>Hernandez, N.S.; Weir, V.R.; Ragnini, K.; Merkel, R.; Zhang, Y.; <lb/>Mace, K.; Rich, M.T.; Christopher, P.R.; Schmidt, H.D. GLP-1 re-<lb/>ceptor signaling in the laterodorsal tegmental nucleus attenuates <lb/>cocaine seeking by activating GABAergic circuits that project to <lb/>the VTA. Mol. Psychiatry, 2021, 26(8), 4394-4408. <lb/>http://dx.doi.org/10.1038/s41380-020-00957-3 PMID: 33257815 <lb/>[27] <lb/>Liu, Z.P.; Wu, C.; Miao, H.; Wu, H. RegNetwork: An integrated <lb/>database of transcriptional and post-transcriptional regulatory net-<lb/>works in human and mouse. Database (Oxford), 2015, 2015, <lb/>bav095. <lb/>http://dx.doi.org/10.1093/database/bav095 PMID: 26424082 <lb/>[28] <lb/>Qiao, L.; Lu, C.; Zang, T.; Dzyuba, B.; Shao, J. Maternal GLP-1 <lb/>receptor activation inhibits fetal growth. Am. J. Physiol. Endo-<lb/>crinol. Metab., 2024, 326(3), ajpendo.00361.2023. <lb/>http://dx.doi.org/10.1152/ajpendo.00361.2023 PMID: 38197791 <lb/>[29] <lb/>Marballi, K.K.; Alganem, K.; Brunwasser, S.J.; Barkatullah, A.; <lb/>Meyers, K.T.; Campbell, J.M.; Ozols, A.B.; Mccullumsmith, R.E.; <lb/>Gallitano, A.L. Identification of activity-induced Egr3-dependent <lb/>genes reveals genes associated with DNA damage response and <lb/>schizophrenia. Transl. Psychiatry, 2022, 12(1), 320. <lb/>http://dx.doi.org/10.1038/s41398-022-02069-8 PMID: 35941129 <lb/>[30] <lb/>Aranäs, C.; Edvardsson, C.E.; Shevchouk, O.T.; Zhang, Q.; Witley, <lb/>S.; Blid, S.S.; Zentveld, L.; Vallöf, D.; Tufvesson-Alm, M.; <lb/>Jerlhag, E. Semaglutide reduces alcohol intake and relapse-like <lb/>drinking in male and female rats. EBioMedicine, 2023, 93, 104642. <lb/>http://dx.doi.org/10.1016/j.ebiom.2023.104642 PMID: 37295046 <lb/>[31] <lb/>Fan, X.; Chen, H.; Jiang, F.; Xu, C.; Wang, Y.; Wang, H.; Li, M.; <lb/>Wei, W.; Song, J.; Zhong, D.; Li, G. Comprehensive analysis of <lb/>cuproptosis-related genes in immune infiltration in ischemic stroke. <lb/>Front. Neurol., 2023, 13, 1077178. <lb/>http://dx.doi.org/10.3389/fneur.2022.1077178 PMID: 36818726 <lb/>[32] <lb/>Jerlhag, E. The therapeutic potential of glucagon-like peptide-1 for <lb/>persons with addictions based on findings from preclinical and <lb/>clinical studies. Front. Pharmacol., 2023, 14, 1063033. <lb/>http://dx.doi.org/10.3389/fphar.2023.1063033 PMID: 37063267 <lb/>[33] <lb/>Tavares, G.; Rosendo-Silva, D.; Simões, F.; Eickhoff, H.; Marques, <lb/>D.; Sacramento, J.F.; Capucho, A.M.; Seiça, R.; Conde, S.V.; <lb/>Matafome, P. Circulating dopamine is regulated by dietary glucose <lb/>and controls glucagon-like 1 peptide action in white adipose tissue. <lb/>Int. J. Mol. Sci., 2023, 24(3), 2464. <lb/>http://dx.doi.org/10.3390/ijms24032464 PMID: 36768789 <lb/>[34] <lb/>Zhang, L.; Li, C.; Zhang, Z.; Zhang, Z.; Jin, Q.Q.; Li, L.; Hölscher, <lb/>C. DA5-CH and semaglutide protect against neurodegeneration and <lb/>reduce α-Synuclein levels in the 6-OHDA parkinson&apos;s disease rat <lb/>model. Parkinsons Dis., 2022, 2022(1), 1-11. <lb/>http://dx.doi.org/10.1155/2022/1428817 PMID: 36419409 <lb/>[35] <lb/>Zhu, C.; Li, H.; Kong, X.; Wang, Y.; Sun, T.; Wang, F. Possible <lb/>mechanisms underlying the effects of glucagon-like peptide-1 re-<lb/>ceptor agonist on cocaine use disorder. Front. Pharmacol., 2022, <lb/>13, 819470. <lb/>http://dx.doi.org/10.3389/fphar.2022.819470 PMID: 35300299 <lb/>[36] <lb/>Konanur, V.R.; Hsu, T.M.; Kanoski, S.E.; Hayes, M.R.; Roitman, <lb/>M.F. Phasic dopamine responses to a food-predictive cue are sup-<lb/>pressed by the glucagon-like peptide-1 receptor agonist Exendin-4. <lb/>Physiol. Behav., 2020, 215, 112771. <lb/>http://dx.doi.org/10.1016/j.physbeh.2019.112771 PMID: 31821815 <lb/>[37] <lb/>Liu, C.; Liu, W.H.; Yang, W.; Chen, L.; Xue, Y.; Chen, X.Y. GLP-<lb/>1 modulated the firing activity of nigral dopaminergic neurons in <lb/>both normal and parkinsonian mice. Neuropharmacology, 2024, <lb/>252, 109946. <lb/>http://dx.doi.org/10.1016/j.neuropharm.2024.109946 PMID: <lb/>38599494 <lb/>[38] <lb/>Merkel, R.; Hernandez, N.; Weir, V.; Zhang, Y.; Rich, M.T.; Crist, <lb/>R.C.; Reiner, B.C.; Schmidt, H.D. An endogenous GLP-1 circuit <lb/>engages VTA GABA neurons to regulate mesolimbic dopamine <lb/>neurons and attenuate cocaine seeking. bioRxiv, 2024, 2024.06. <lb/>http://dx.doi.org/10.1101/2024.06.20.599574 <lb/>[39] <lb/>Fortin, S.M.; Roitman, M.F. Central GLP-1 receptor activation <lb/>modulates cocaine-evoked phasic dopamine signaling in the nucle-<lb/>us accumbens core. Physiol. Behav., 2017, 176, 17-25. <lb/>http://dx.doi.org/10.1016/j.physbeh.2017.03.019 PMID: 28315693 <lb/>[40] <lb/>Reddy, I.A.; Pino, J.A.; Weikop, P.; Osses, N.; Sørensen, G.; Ber-<lb/>ing, T.; Valle, C.; Bluett, R.J.; Erreger, K.; Wortwein, G.; Reyes, <lb/>J.G.; Graham, D.; Stanwood, G.D.; Hackett, T.A.; Patel, S.; Fink-<lb/>Jensen, A.; Torres, G.E.; Galli, A. Glucagon-like peptide 1 receptor <lb/>activation regulates cocaine actions and dopamine homeostasis in <lb/>the lateral septum by decreasing arachidonic acid levels. Transl. <lb/>Psychiatry, 2016, 6(5), e809-e809. <lb/>http://dx.doi.org/10.1038/tp.2016.86 PMID: 27187231 <lb/>[41] <lb/>Elasbali, A.M.; Al-Soud, W.A.; Mousa Elayyan, A.E.; Al-Oanzi, <lb/>Z.H.; Alhassan, H.H.; Mohamed, B.M.; Alanazi, H.H.; Ashraf, <lb/>M.S.; Moiz, S.; Patel, M.; Patel, M.; Adnan, M. Integrating net-<lb/>work pharmacology approaches for the investigation of multi-target <lb/>pharmacological mechanism of 6-shogaol against cervical cancer. <lb/>J. Biomol. Struct. Dyn., 2023, 41(23), 14135-14151. <lb/>http://dx.doi.org/10.1080/07391102.2023.2191719 PMID: <lb/>36943780 <lb/>[42] <lb/>Falk, S.; Petersen, J.; Svendsen, C.; Romero-Leguizamón, C.R.; <lb/>Jørgensen, S.H.; Krauth, N.; Ludwig, M.Q.; Lundø, K.; Roostalu, <lb/>U.; Skovbjerg, G.; Nielsen, D.A.G.; Ejdrup, A.L.; Pers, T.H.; <lb/>Dmytriyeva, O.; Hecksher-Sørensen, J.; Gether, U.; Kohlmeier, <lb/>K.A.; Clemmensen, C. GLP-1 and nicotine combination therapy <lb/>engages hypothalamic and mesolimbic pathways to reverse obesity. <lb/>Cell Rep., 2023, 42(5), 112466. <lb/>http://dx.doi.org/10.1016/j.celrep.2023.112466 PMID: 37148870 <lb/>[43] <lb/>Borsook, D.; Linnman, C.; Faria, V.; Strassman, A.M.; Becerra, L.; <lb/>Elman, I. Reward deficiency and anti-reward in pain chronification. <lb/>Neurosci. Biobehav. Rev., 2016, 68, 282-297. <lb/>http://dx.doi.org/10.1016/j.neubiorev.2016.05.033 PMID: <lb/>27246519 <lb/>[44] <lb/>Blum, K.; McLaughlin, T.; Bowirrat, A.; Modestino, E.J.; Baron, <lb/>D.; Gomez, L.L.; Ceccanti, M.; Braverman, E.R.; Thanos, P.K.; <lb/>Cadet, J.L.; Elman, I.; Badgaiyan, R.D.; Jalali, R.; Green, R.; Sim-<lb/>patico, T.A.; Gupta, A.; Gold, M.S. Reward deficiency syndrome <lb/>(RDS) surprisingly is evolutionary and found everywhere: Is it <lb/>&quot;blowin&apos;in the wind&quot;? J. Pers. Med., 2022, 12(2), 321. <lb/>http://dx.doi.org/10.3390/jpm12020321 PMID: 35207809 <lb/>[45] <lb/>Gruber, J.; Hanssen, R.; Qubad, M.; Bouzouina, A.; Schack, V.; <lb/>Sochor, H.; Schiweck, C.; Aichholzer, M.; Matura, S.; Slattery, <lb/>D.A.; Zopf, Y.; Borgland, S.L.; Reif, A.; Thanarajah, S.E. Impact <lb/>of insulin and insulin resistance on brain dopamine signalling and <lb/>reward processing -An underexplored mechanism in the patho-<lb/>physiology of depression? Neurosci. Biobehav. Rev., 2023, 149, <lb/>105179. <lb/>http://dx.doi.org/10.1016/j.neubiorev.2023.105179 PMID: <lb/>37059404 <lb/>[46] <lb/>Gondré-Lewis, M.C.; Bassey, R.; Blum, K. Pre-clinical models of <lb/>reward deficiency syndrome: A behavioral octopus. Neurosci. Bi-<lb/>obehav. Rev., 2020, 115, 164-188. <lb/>http://dx.doi.org/10.1016/j.neubiorev.2020.04.021 PMID: <lb/>32360413 <lb/>[47] <lb/>Wilson, J.B.; Epstein, M.; Lopez, B.; Brown, A.K.; Lutfy, K.; <lb/>Friedman, T.C. The role of neurochemicals, stress hormones and <lb/>immune system in the positive feedback loops between diabetes, <lb/>obesity and depression. Front. Endocrinol. (Lausanne), 2023, 14, <lb/>1224612. <lb/>http://dx.doi.org/10.3389/fendo.2023.1224612 PMID: 37664841 <lb/>[48] <lb/>Elman, I.; Borsook, D.; Volkow, N.D. Pain and suicidality: Insights <lb/>from reward and addiction neuroscience. Prog. Neurobiol., 2013, <lb/>109, 1-27. <lb/>http://dx.doi.org/10.1016/j.pneurobio.2013.06.003 PMID: <lb/>23827972 <lb/>[49] <lb/>Blum, K.; Blum, K.; Febo, M.; Baron, D.; Modestino, E.J.; Elman, <lb/>I.; Badgaiyan, R.D. Molecular role of dopamine in anhedonia <lb/>linked to reward deficiency syndrome RDS and anti-reward sys-<lb/>tems. Front. Biosci. (Schol. Ed.), 2018, 10(2), 309-325. <lb/>http://dx.doi.org/10.2741/s518 PMID: 29293435 <lb/>[50] <lb/>Nephew, B.; Murgatroyd, C.; Pittet, F.; Febo, M. Brain reward <lb/>pathway dysfunction in maternal depression and addiction: A pre-<lb/>sent and future transgenerational risk. J. Reward Defic. Syndr., <lb/>2015, 1(3), 105-116. <lb/></listBibl>

			<page>994 </page>
				
			<note place="headnote">Current Neuropharmacology, 2025, Vol. 23, No. 8 <lb/>Sharafshah et al. <lb/></note>

			<listBibl>http://dx.doi.org/10.17756/jrds.2015-017 PMID: 27617302 <lb/>[51] <lb/>Arango-Lievano, M.; Kaplitt, M.G. Comorbidity between depres-<lb/>sion and addiction-Towards a common molecular target? Med Sci, <lb/>2015, 3(5), 546 -550. <lb/>[52] <lb/>Zhao, X.; Wu, S.; Li, X.; Liu, Z.; Lu, W.; Lin, K.; Shao, R. Com-<lb/>mon neural deficits across reward functions in major depression: A <lb/>meta-analysis of fMRI studies. Psychol. Med., 2024, 54(11), 2794-<lb/>2806. <lb/>http://dx.doi.org/10.1017/S0033291724001235 PMID: 38777630 <lb/>[53] <lb/>Must, A.; Szabó, Z.; Bódi, N.; Szász, A.; Janka, Z.; Kéri, S. Sensi-<lb/>tivity to reward and punishment and the prefrontal cortex in major <lb/>depression. J. Affect. Disord., 2006, 90(2-3), 209-215. <lb/>http://dx.doi.org/10.1016/j.jad.2005.12.005 PMID: 16412520 <lb/>[54] <lb/>Salamone, J.D.; Correa, M.; Yohn, S.; Lopez Cruz, L.; San Miguel, <lb/>N.; Alatorre, L. The pharmacology of effort-related choice behav-<lb/>ior: Dopamine, depression, and individual differences. Behav. Pro-<lb/>cesses, 2016, 127, 3-17. <lb/>http://dx.doi.org/10.1016/j.beproc.2016.02.008 PMID: 26899746 <lb/>[55] <lb/>Park, I.H.; Lee, B.C.; Kim, J.J.; Kim, J.I.; Koo, M.S. Effort-based <lb/>reinforcement processing and functional connectivity underlying <lb/>amotivation in medicated patients with depression and schizophre-<lb/>nia. J. Neurosci., 2017, 37(16), 4370-4380. <lb/>http://dx.doi.org/10.1523/JNEUROSCI.2524-16.2017 PMID: <lb/>28283562 <lb/>[56] <lb/>Sapuram, V.R.; Vrshek-Schallhorn, S.; Hilt, L.M.; Stroud, C.B. <lb/>Dopaminergic genetic variation in young adolescents: Associations <lb/>with sensation-seeking. Res. Child. Adolesc. Psychopathol., 2021, <lb/>49(10), 1259-1274. <lb/>http://dx.doi.org/10.1007/s10802-021-00823-y PMID: 33963956 <lb/>[57] <lb/>Bergamini, G.; Sigrist, H.; Ferger, B.; Singewald, N.; Seifritz, E.; <lb/>Pryce, C.R. Depletion of nucleus accumbens dopamine leads to <lb/>impaired reward and aversion processing in mice: Relevance to <lb/>motivation pathologies. Neuropharmacology, 2016, 109, 306-319. <lb/>http://dx.doi.org/10.1016/j.neuropharm.2016.03.048 PMID: <lb/>27036890 <lb/>[58] <lb/>Lutz, P.E.; Kieffer, B.L. Opioid receptors: Distinct roles in mood <lb/>disorders. Trends Neurosci., 2013, 36(3), 195-206. <lb/>http://dx.doi.org/10.1016/j.tins.2012.11.002 PMID: 23219016 <lb/>[59] <lb/>Wolters, E.C.; van der Werf, Y.D.; van den Heuvel, O.A. Parkin-<lb/>son&apos;s disease-related disorders in the impulsive-compulsive spec-<lb/>trum. J. Neurol., 2008, 255(S5)(Suppl. 5), 48-56. <lb/>http://dx.doi.org/10.1007/s00415-008-5010-5 PMID: 18787882 <lb/>[60] <lb/>Thanos, P.K.; Blum, K.; McCarthy, M.; Senior, D.; Watts, S.; <lb/>Connor, C.; Hammond, N.; Hadjiargyrou, M.; Komatsu, D.; Stei-<lb/>ner, H. Combined chronic oral methylphenidate and fluoxetine <lb/>treatment during adolescence: Effects on behavior. Curr. Pharm. <lb/>Biotechnol., 2023, 24(10), 1307-1314. <lb/>http://dx.doi.org/10.2174/1389201024666221028092342 PMID: <lb/>36306463 <lb/>[61] <lb/>Rothman, R.B.; Blough, B.E.; Baumann, M.H. Dual dopa-<lb/>mine/serotonin releasers as potential medications for stimulante <lb/>and alcohol addictions. AAPS J., 2007, 9(1), E1-E10. <lb/>http://dx.doi.org/10.1208/aapsj0901001 PMID: 17408232 <lb/>[62] <lb/>Ribeiro, G.; Maia, A.; Cotovio, G.; Oliveira, F.P.M.; Costa, D.C.; <lb/>Oliveira-Maia, A.J. Striatal dopamine D2-like receptors availability <lb/>in obesity and its modulation by bariatric surgery: A systematic re-<lb/>view and meta-analysis. Sci. Rep., 2023, 13(1), 4959. <lb/>http://dx.doi.org/10.1038/s41598-023-31250-2 PMID: 36973321 <lb/>[63] <lb/>Kanoski, S.E.; Hayes, M.R.; Skibicka, K.P. GLP-1 and weight loss: <lb/>Unraveling the diverse neural circuitry. Am. J. Physiol. Regul. In-<lb/>tegr. Comp. Physiol., 2016, 310(10), R885-R895. <lb/>http://dx.doi.org/10.1152/ajpregu.00520.2015 PMID: 27030669 <lb/>[64] <lb/>Yorgason, J.T.; Wadsworth, H.A.; Anderson, E.J.; Williams, B.M.; <lb/>Brundage, J.N.; Hedges, D.M.; Stockard, A.L.; Jones, S.T.; Arthur, <lb/>S.B.; Hansen, D.M.; Schilaty, N.D.; Jang, E.Y.; Lee, A.M.; Wall-<lb/>ner, M.; Steffensen, S.C. Modulation of dopamine release by etha-<lb/>nol is mediated by atypical GABAA receptors on cholinergic inter-<lb/>neurons in the nucleus accumbens. Addict. Biol., 2022, 27(1), <lb/>e13108. <lb/>http://dx.doi.org/10.1111/adb.13108 PMID: 34713509 <lb/>[65] <lb/>EMA statement on ongoing review of GLP-1 receptor agonists. <lb/>2023. Available from : https://www.ema.europa.eu/en/news/ema-<lb/>statement-ongoing-review-glp-1-receptor-agonists <lb/>[66] <lb/>Terhune, R.R.C. Wegovy, other weight-loss drugs scrutinized over <lb/>reports of suicidal thoughts. 2023. Available from: <lb/>https://www.reuters.com/business/healthcare-pharmaceuticals/ <lb/>wegovy-other-weight-loss-drugs-scrutinized-over-reports-suicidal-<lb/>thoughts-2023-09-28/ <lb/>[67] <lb/>Ruggiero, R.; Mascolo, A.; Spezzaferri, A.; Carpentieri, C.; Torel-<lb/>la, D.; Sportiello, L.; Rossi, F.; Paolisso, G.; Capuano, A. Gluca-<lb/>gon-like Peptide-1 receptor agonists and suicidal ideation: Analysis <lb/>of real-word data collected in the European Pharmacovigilance da-<lb/>tabase. Pharmaceuticals, 2024, 17(2), 147. <lb/>http://dx.doi.org/10.3390/ph17020147 PMID: 38399362 <lb/>[68] <lb/>Tobaiqy, M.; Elkout, H. Psychiatric adverse events associated with <lb/>semaglutide, liraglutide and tirzepatide: A pharmacovigilance anal-<lb/>ysis of individual case safety reports submitted to the EudraVigi-<lb/>lance database. Int. J. Clin. Pharm., 2024, 46(2), 488-495. <lb/>http://dx.doi.org/10.1007/s11096-023-01694-7 PMID: 38265519 <lb/>[69] <lb/>Maideen, N.M.P.; Al Rashid, S. Suicidal thoughts and self-<lb/>injurious behavior associated with glucagon-like peptide-1 receptor <lb/>agonists -A review. Curr. Drug Saf., 2024, 19 <lb/>http://dx.doi.org/10.2174/0115748863301925240507044637 <lb/>PMID: 38766830 <lb/>[70] <lb/>Salvo, F.; Faillie, J.L. GLP-1 receptor agonists and suicidality-<lb/>caution is needed. JAMA Netw. Open, 2024, 7(8), e2423335-<lb/>e2423335. <lb/>http://dx.doi.org/10.1001/jamanetworkopen.2024.23335 PMID: <lb/>39163050 <lb/>[71] <lb/>Driggin, E.; Goyal, P. Malnutrition and Sarcopenia as reasons for <lb/>caution with GLP-1 receptor agonist use in HFpEF. J. Card. Fail., <lb/>2024, 30(4), 610-612. <lb/>http://dx.doi.org/10.1016/j.cardfail.2024.01.005 PMID: 38301742 <lb/>[72] <lb/>Scheen, A.J. Antidiabetic agents and risk of atrial fibrilla-<lb/>tion/flutter: A comparative critical analysis with a focus on differ-<lb/>ences between SGLT2 inhibitors and GLP-1 receptor agonists. Di-<lb/>abetes Metab., 2022, 48(6), 101390. <lb/>http://dx.doi.org/10.1016/j.diabet.2022.101390 PMID: 36170946 <lb/>[73] <lb/>Leehey, D.J.; Rahman, M.A.; Borys, E.; Picken, M.M.; Clise, C.E. <lb/>Acute kidney injury associated with semaglutide. Kidney Med., <lb/>2021, 3(2), 282-285. <lb/>http://dx.doi.org/10.1016/j.xkme.2020.10.008 PMID: 33851124 <lb/>[74] <lb/>Sun, Y.; Fan, L.; Meng, J.; Zhang, F.; Zhang, D.; Mei, Q. Should <lb/>GLP-1 receptor agonists be used with caution in high risk popula-<lb/>tion for colorectal cancer? Med. Hypotheses, 2014, 82(3), 255-256. <lb/>http://dx.doi.org/10.1016/j.mehy.2013.11.034 PMID: 24424394 <lb/>[75] <lb/>Borab, Z.M.; Fisher, S.M.; Borab, Z.M.; Gimenez, A.; Raskin, P.; <lb/>Valek, T.; Rohrich, R.J. Emerging role of Semaglutide and GLP-1 <lb/>agonist medications in plastic surgery: A note of caution. Plast Re-<lb/>constr Surg., 2021, 154(3), 629-631. <lb/>http://dx.doi.org/10.1097/PRS.0000000000011418 <lb/>[76] <lb/>Nohara, H.; Nakashima, R.; Kamei, S.; Fujikawa, H.; Ueno-Shuto, <lb/>K.; Kawakami, T.; Eto, Y.; Suico, M.A.; Li, J.D.; Kai, H.; Shuto, <lb/>T. Intratracheal GLP-1 receptor agonist treatment up-regulates mu-<lb/>cin via p38 and exacerbates emphysematous phenotype in mucus <lb/>hypersecretory obstructive lung diseases. Biochem. Biophys. Res. <lb/>Commun., 2020, 524(2), 332-339. <lb/>http://dx.doi.org/10.1016/j.bbrc.2020.01.081 PMID: 31996306 <lb/>[77] <lb/>Nguyen, A.; Smith, E.; Hashemy, H.; Agarwal, S.M.; Hahn, M.K.; <lb/>Paterson, A.D.; Dash, S. Glucagon-like-peptide 1 receptor agonism <lb/>and attempted suicide: A Mendelian randomisation study to assess <lb/>a potential causal association. Clin. Obes., 2024, 14(4), e12676. <lb/>http://dx.doi.org/10.1111/cob.12676 PMID: 38778795 <lb/>[78] <lb/>Zhou, J.; Zheng, Y.; Xu, B.; Long, S.; Zhu, L.; Liu, Y.; Li, C.; <lb/>Zhang, Y.; Liu, M.; Wu, X. Exploration of the potential association <lb/>between GLP-1 receptor agonists and suicidal or self-injurious be-<lb/>haviors: A pharmacovigilance study based on the FDA Adverse <lb/>Event Reporting System database. BMC Med., 2024, 22(1), 65. <lb/>http://dx.doi.org/10.1186/s12916-024-03274-6 PMID: 38355513 <lb/>[79] <lb/>Wang, W.; Volkow, N.D.; Berger, N.A.; Davis, P.B.; Kaelber, <lb/>D.C.; Xu, R. Association of semaglutide with risk of suicidal idea-<lb/>tion in a real-world cohort. Nat. Med., 2024, 30(1), 168-176. <lb/>http://dx.doi.org/10.1038/s41591-023-02672-2 PMID: 38182782 <lb/>[80] <lb/>Aschenbrenner, D.S. Preliminary review finds no link between <lb/>GLP-1 receptor agonists and suicidality. Am. J. Nurs., 2024, <lb/>124(5), 20. <lb/></listBibl>

			<note place="headnote">PGx of GLP1 Agonists and GARS <lb/>Current Neuropharmacology, 2025, Vol. 23, No. 8 </note>
				
			<page>995 <lb/></page>

			<listBibl>http://dx.doi.org/10.1097/01.NAJ.0001016352.54091.a1 PMID: <lb/>38661695 <lb/>[81] <lb/>Plum, L.; Belgardt, B.F.; Brüning, J.C. Central insulin action in <lb/>energy and glucose homeostasis. J. Clin. Invest., 2006, 116(7), <lb/>1761-1766. <lb/>http://dx.doi.org/10.1172/JCI29063 PMID: 16823473 <lb/>[82] <lb/>Patti, M.E.; Butte, A.J.; Crunkhorn, S.; Cusi, K.; Berria, R.; <lb/>Kashyap, S.; Miyazaki, Y.; Kohane, I.; Costello, M.; Saccone, R.; <lb/>Landaker, E.J.; Goldfine, A.B.; Mun, E.; DeFronzo, R.; Finlayson, <lb/>J.; Kahn, C.R.; Mandarino, L.J. Coordinated reduction of genes of <lb/>oxidative metabolism in humans with insulin resistance and diabe-<lb/>tes: Potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. USA, <lb/>2003, 100(14), 8466-8471. <lb/>http://dx.doi.org/10.1073/pnas.1032913100 PMID: 12832613 <lb/>[83] <lb/>Gardner, A.; Boles, R.G. Beyond the serotonin hypothesis: Mito-<lb/>chondria, inflammation and neurodegeneration in major depression <lb/>and affective spectrum disorders. Prog. Neuropsychopharmacol. <lb/>Biol. Psychiatry, 2011, 35(3), 730-743. <lb/>http://dx.doi.org/10.1016/j.pnpbp.2010.07.030 PMID: 20691744 <lb/>[84] <lb/>Agarwal, S.M.; Caravaggio, F.; Costa-Dookhan, K.A.; Castellani, <lb/>L.; Kowalchuk, C.; Asgariroozbehani, R.; Graff-Guerrero, A.; <lb/>Hahn, M. Brain insulin action in schizophrenia: Something bor-<lb/>rowed and something new. Neuropharmacology, 2020, 163, <lb/>107633. <lb/>http://dx.doi.org/10.1016/j.neuropharm.2019.05.010 PMID: <lb/>31077731 <lb/>[85] <lb/>Nag, M. Effect of chlorpromazine, imipramine and lithium on <lb/>MAO-A and MAO-B activity in rat brain mitochondria. Indian J. <lb/>Exp. Biol., 2004, 42(9), 941-944. <lb/>PMID: 15462192 <lb/>[86] <lb/>Herculano-Houzel, S. The glia/neuron ratio: How it varies uniform-<lb/>ly across brain structures and species and what that means for brain <lb/>physiology and evolution. Glia, 2014, 62(9), 1377-1391. <lb/>http://dx.doi.org/10.1002/glia.22683 PMID: 24807023 <lb/>[87] <lb/>Kleinridders, A.; Cai, W.; Cappellucci, L.; Ghazarian, A.; Collins, <lb/>W.R.; Vienberg, S.G.; Pothos, E.N.; Kahn, C.R. Insulin resistance <lb/>in brain alters dopamine turnover and causes behavioral disorders. <lb/>Proc. Natl. Acad. Sci. USA, 2015, 112(11), 3463-3468. <lb/>http://dx.doi.org/10.1073/pnas.1500877112 PMID: 25733901 <lb/>[88] <lb/>Stuart, M.J.; Baune, B.T. Depression and type 2 diabetes: Inflam-<lb/>matory mechanisms of a psychoneuroendocrine co-morbidity. Neu-<lb/>rosci. Biobehav. Rev., 2012, 36(1), 658-676. <lb/>http://dx.doi.org/10.1016/j.neubiorev.2011.10.001 PMID: <lb/>22020230 <lb/>[89] <lb/>Sadek, M.A.; Kandil, E.A.; El Sayed, N.S.; Sayed, H.M.; Rabie, <lb/>M.A. Semaglutide, a novel glucagon-like peptide-1 agonist, <lb/>amends experimental autoimmune encephalomyelitis-induced mul-<lb/>tiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β <lb/>pathway. Int. Immunopharmacol., 2023, 115, 109647. <lb/>http://dx.doi.org/10.1016/j.intimp.2022.109647 PMID: 36584570 <lb/>[90] <lb/>Schoretsanitis, G.; Weiler, S.; Barbui, C.; Raschi, E.; Gastaldon, C. <lb/>Disproportionality analysis from World Health Organization data <lb/>on semaglutide, liraglutide, and suicidality. JAMA Netw. Open, <lb/>2024, 7(8), e2423385-e2423385. <lb/>http://dx.doi.org/10.1001/jamanetworkopen.2024.23385 <lb/>PMID: <lb/>39163046 <lb/>[91] <lb/>Blum, K.; Madigan, M.A.; Fuehrlein, B.; Thanos, P.K.; Lewand-<lb/>rowski, K.U.; Sharafshah, A.; Elman, I.; Baron, D.; Bowirrat, A.; <lb/>Pinhasov, A.; Braverman, E.R.; Zeine, F.; Jafari, N.; Gold, M.S. <lb/>Genes and Genetic Testing in Addiction Medicine. <lb/>https://www.sciencedirect.com/referencework/9780128093245/refe <lb/>rence-module-in-neuroscience-and-biobehavioral-psychology efer-<lb/>ence Module in Neuroscience and Biobehavioral Psychology 2024. <lb/>[92] <lb/>Tobaiqy, M.; Elkout. H. Psychiatric adverse events associated with <lb/>semaglutide, liraglutide and tirzepatide: A pharmacovigilance anal-<lb/>ysis of individual case safety reports submitted to the EudraVigi-<lb/>lance database. Int. J. Clin. Pharm., 2024, 46(2), 488-495. <lb/>doi: 10.1007/s11096-023-01694-7 PMID: 38265519 <lb/>[93] <lb/>Chen. W.; Cai, P.; Zou, W.; Fu, Z. Psychiatric adverse events asso-<lb/>ciated with GLP-1 receptor agonists: A real-world pharmacovigi-<lb/>lance study based on the FDA Adverse event reporting system da-<lb/>tabase. Front Endocrinol. (Lausanne)., 2024, 15, 1330936. <lb/>doi: 10.3389/fendo.2024.1330936. PMID: 38390214 </listBibl>


	</text>
</tei>
